

Evidence of escape of SARS-CoV-2 variant B.1.351 from 1

Cell

184, 2348-2361.e6

DOI: [10.1016/j.cell.2021.02.037](https://doi.org/10.1016/j.cell.2021.02.037)

Citation Report

#	ARTICLE	IF	CITATIONS
1	COVID-19 vaccines. <i>Farmacist Ro</i> , 2021, 1, 7.	0.0	0
2	Clinical Characteristics of COVID-19 by SARS-CoV-2 Gamma Variant in Vaccinated and Non-Vaccinated Healthcare Workers. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
3	Transmission of SARS-CoV-2 Delta Variant Among Vaccinated Healthcare Workers, Vietnam. <i>SSRN Electronic Journal</i> , 0, , .	0.4	4
5	Preclinical Study of DNA Vaccines Targeting SARS-CoV-2. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
6	Immune evasion of SARS-CoV-2 variants of concern is driven by low affinity to neutralizing antibodies. <i>Chemical Communications</i> , 2021, 57, 6094-6097.	2.2	18
7	Prior aerosol infection with lineage A SARS-CoV-2 variant protects hamsters from disease, but not reinfection with B.1.351 SARS-CoV-2 variant. <i>Emerging Microbes and Infections</i> , 2021, 10, 1284-1292.	3.0	25
8	SARS-CoV-2 infection and disease outcomes in non-human primate models: advances and implications. <i>Emerging Microbes and Infections</i> , 2021, 10, 1881-1889.	3.0	10
9	Live virus neutralization testing in convalescent patients and subjects vaccinated against 19A, 20B, 20I/501Y.V1 and 20H/501Y.V2 isolates of SARS-CoV-2. <i>Emerging Microbes and Infections</i> , 2021, 10, 1499-1502.	3.0	9
10	Development of potent and effective synthetic SARS-CoV-2 neutralizing nanobodies. <i>MAbs</i> , 2021, 13, 1958663.	2.6	16
11	The challenge of emerging SARS-CoV-2 mutants to vaccine development. <i>Journal of Genetics and Genomics</i> , 2021, 48, 102-106.	1.7	19
14	Nanotechnology advances in pathogen- and host-targeted antiviral delivery: multipronged therapeutic intervention for pandemic control. <i>Drug Delivery and Translational Research</i> , 2021, 11, 1420-1437.	3.0	18
21	B-Cell Memory Responses to Variant Viral Antigens. <i>Viruses</i> , 2021, 13, 565.	1.5	10
24	SARS-CoV-2 vaccination efficacy on hospitalisation and variants. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2021, , 100867.	0.6	0
28	COVID-19: viral origins, vaccine fears and risk perceptions. <i>Public Health</i> , 2021, 196, A1-A2.	1.4	1
30	<sc>SARS-CoV-2</sc> biology and variants: anticipation of viral evolution and what needs to be done. <i>Environmental Microbiology</i> , 2021, 23, 2339-2363.	1.8	30
31	SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape. <i>Cell</i> , 2021, 184, 2362-2371.e9.	13.5	332
39	Global Discrepancies between Numbers of Available SARS-CoV-2 Genomes and Human Development Indexes at Country Scales. <i>Viruses</i> , 2021, 13, 775.	1.5	7
41	SARS-CoV-2 mRNA vaccines induce broad CD4+ T cell responses that recognize SARS-CoV-2 variants and HCoV-NL63. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	154

#	ARTICLE	IF	CITATIONS
42	Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals after mRNA vaccination. <i>Science Immunology</i> , 2021, 6, .	5.6	556
43	A review on the immune responses against novel emerging coronavirus (SARS-CoV-2). <i>Immunologic Research</i> , 2021, 69, 213-224.	1.3	27
48	Insights into SARS-CoV-2's Mutations for Evading Human Antibodies: Sacrifice and Survival. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 2820-2826.	2.9	49
49	Effects of SARS-CoV-2 variants on vaccine efficacy and response strategies. <i>Expert Review of Vaccines</i> , 2021, 20, 365-373.	2.0	139
53	Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. <i>Science</i> , 2021, 372, 815-821.	6.0	1,125
55	Mild Symptomatic SARS-CoV-2 P.1 (B.1.1.28) Infection in a Fully Vaccinated 83-Year-Old Man. <i>Pathogens</i> , 2021, 10, 614.	1.2	11
56	Kinetics of Neutralizing Antibodies of COVID-19 Patients Tested Using Clinical D614G, B.1.1.7, and B.1.351 Isolates in Microneutralization Assays. <i>Viruses</i> , 2021, 13, 996.	1.5	14
58	BNT162b2 Messenger RNA Vaccination Did Not Prevent an Outbreak of Severe Acute Respiratory Syndrome Coronavirus 2 Variant 501Y.V2 in an Elderly Nursing Home but Reduced Transmission and Disease Severity. <i>Clinical Infectious Diseases</i> , 2022, 74, 517-520.	2.9	36
60	Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants. <i>Science</i> , 2021, 373, 818-823.	6.0	309
64	A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection. <i>Cell Host and Microbe</i> , 2021, 29, 806-818.e6.	5.1	49
66	A higher flexibility at the SARS-CoV-2 main protease active site compared to SARS-CoV and its potentialities for new inhibitor virtual screening targeting multi-conformers. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 9214-9234.	2.0	7
69	SARS-CoV-2 vaccines: anamnestic response in previously infected recipients. <i>Cell Research</i> , 2021, 31, 827-828.	5.7	15
75	Surveillance for SARS-CoV-2 variants of concern in the Australian context. <i>Medical Journal of Australia</i> , 2021, 214, 500.	0.8	9
78	Elucidating reasons of COVID-19 re-infection and its management strategies. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2021, 15, 1001-1006.	1.8	29
79	SARS-CoV-2 variants of concern partially escape humoral but not T cell responses in COVID-19 convalescent donors and vaccine recipients. <i>Science Immunology</i> , 2021, 6, .	5.6	455
80	Antibody evasion by the P.1 strain of SARS-CoV-2. <i>Cell</i> , 2021, 184, 2939-2954.e9.	13.5	519
81	Interplay between Emerging SARS-CoV-2 Variants and Pandemic Control. <i>New England Journal of Medicine</i> , 2021, 384, 1952-1954.	13.9	19
82	The Spike of Concern—The Novel Variants of SARS-CoV-2. <i>Viruses</i> , 2021, 13, 1002.	1.5	92

#	ARTICLE	IF	CITATIONS
84	Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines. <i>Cell Research</i> , 2021, 31, 732-741.	5.7	124
97	Diverse immunoglobulin gene usage and convergent epitope targeting in neutralizing antibody responses to SARS-CoV-2. <i>Cell Reports</i> , 2021, 35, 109109.	2.9	21
98	A bivalent recombinant vaccine targeting the S1 protein induces neutralizing antibodies against both SARS-CoV-2 variants and wild-type of the virus. <i>MedComm</i> , 2021, 2, 430-441.	3.1	37
99	<scp>COVID</scp>â€19: vaccination problems. <i>Environmental Microbiology</i> , 2021, 23, 2878-2890.	1.8	46
100	Immune response to SARS-CoV-2 variants of concern in vaccinated individuals. <i>Nature Communications</i> , 2021, 12, 3109.	5.8	118
104	Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. <i>Nature Medicine</i> , 2021, 27, 1205-1211.	15.2	3,133
109	Present variants of concern and variants of interest of severe acute respiratory syndrome coronavirus 2: Their significant mutations in Sâ€glycoprotein, infectivity, reâ€infectivity, immune escape and vaccines activity. <i>Reviews in Medical Virology</i> , 2022, 32, e2270.	3.9	71
110	New variants of SARS-CoV-2. <i>Revista Espanola De Quimioterapia</i> , 2021, 34, 419-428.	0.5	49
111	A reasoned approach towards administering COVIDâ€19 vaccines to pregnant women. <i>Prenatal Diagnosis</i> , 2021, 41, 1018-1035.	1.1	9
112	The significance and impact of SARSâ€CoVâ€2 variants of concern in pediatric solid organ transplantation: More unknowns than knowns. <i>Pediatric Transplantation</i> , 2021, 25, e14071.	0.5	1
113	Severe Acute Respiratory Syndrome Coronavirus 2: The Emergence of Important Genetic Variants and Testing Options for Clinical Laboratories. <i>Clinical Microbiology Newsletter</i> , 2021, 43, 89-96.	0.4	5
116	SARS-CoV-2 Portrayed against HIV: Contrary Viral Strategies in Similar Disguise. <i>Microorganisms</i> , 2021, 9, 1389.	1.6	4
117	Comparative Analysis of Emerging B.1.1.7+E484K SARS-CoV-2 Isolates. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab300.	0.4	16
118	The pivotal roles of the host immune response in the fine-tuning the infection and the development of the vaccines for SARS-CoV-2. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 3297-3309.	1.4	6
119	Safety and Efficacy of Single-Dose Ad26.COVS Vaccine against Covid-19. <i>New England Journal of Medicine</i> , 2021, 384, 2187-2201.	13.9	1,954
120	An ACE2 Triple Decoy that neutralizes SARS-CoV-2 shows enhanced affinity for virus variants. <i>Scientific Reports</i> , 2021, 11, 12740.	1.6	54
123	Immune Evasion of SARS-CoV-2 Emerging Variants: What Have We Learnt So Far?. <i>Viruses</i> , 2021, 13, 1192.	1.5	150
124	Meta-Analysis and Structural Dynamics of the Emergence of Genetic Variants of SARS-CoV-2. <i>Frontiers in Microbiology</i> , 2021, 12, 676314.	1.5	17

#	ARTICLE	IF	CITATIONS
125	Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant. <i>Immunity</i> , 2021, 54, 1276-1289.e6.	6.6	112
130	In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains. <i>Nature</i> , 2021, 596, 103-108.	13.7	222
134	CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2. <i>Nature Communications</i> , 2021, 12, 4048.	5.8	45
135	Engineered ACE2 receptor therapy overcomes mutational escape of SARS-CoV-2. <i>Nature Communications</i> , 2021, 12, 3802.	5.8	101
137	Controlling the pandemic during the SARS-CoV-2 vaccination rollout. <i>Nature Communications</i> , 2021, 12, 3674.	5.8	98
139	Impact of spike genetic variants in vaccines against SARS-CoV-2. <i>Vacunas (English Edition)</i> , 2021, 22, 59-61.	0.3	0
142	Structure-function relations of the SARS-CoV-2 spike protein and impact of mutations in the variants of concern. <i>Comptes Rendus - Biologies</i> , 2021, 344, 77-110.	0.1	4
143	SARS-CoV-2 vaccination efficacy on hospitalisation and variants. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2021, 40, 100874.	0.6	2
146	Genetic modification to design a stable yeast-expressed recombinant SARS-CoV-2 receptor binding domain as a COVID-19 vaccine candidate. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2021, 1865, 129893.	1.1	49
147	Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals. <i>Nature Medicine</i> , 2021, 27, 1379-1384.	15.2	296
150	Adaptation of the endemic coronaviruses HCoV-OC43 and HCoV-229E to the human host. <i>Virus Evolution</i> , 2021, 7, veab061.	2.2	12
152	COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants. <i>Nature Communications</i> , 2021, 12, 3991.	5.8	241
153	The SARS-CoV-2 B.1.351 lineage (VOC Î²) is outgrowing the B.1.1.7 lineage (VOC Î±) in some French regions in April 2021. <i>Eurosurveillance</i> , 2021, 26, .	3.9	24
156	SARS-CoV-2 Spike Protein Stabilized in the Closed State Induces Potent Neutralizing Responses. <i>Journal of Virology</i> , 2021, 95, e0020321.	1.5	35
158	ACE2 Receptor-Modified Algae-Based Microrobot for Removal of SARS-CoV-2 in Wastewater. <i>Journal of the American Chemical Society</i> , 2021, 143, 12194-12201.	6.6	42
159	Personalized health and the coronavirus vaccinesâ€”Do individual genetics matter?. <i>BioEssays</i> , 2021, 43, e2100087.	1.2	9
160	Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19. <i>New England Journal of Medicine</i> , 2021, 385, 1382-1392.	13.9	534
161	Is there a place for mesenchymal stromal cell-based therapies in the therapeutic armamentarium against COVID-19?. <i>Stem Cell Research and Therapy</i> , 2021, 12, 425.	2.4	15

#	ARTICLE	IF	CITATIONS
162	An intranasal vaccine durably protects against SARS-CoV-2 variants in mice. <i>Cell Reports</i> , 2021, 36, 109452.	2.9	90
163	Advances in the computational landscape for repurposed drugs against COVID-19. <i>Drug Discovery Today</i> , 2021, 26, 2800-2815.	3.2	19
165	Full-Length Recombinant hSP-D Binds and Inhibits SARS-CoV-2. <i>Biomolecules</i> , 2021, 11, 1114.	1.8	13
167	Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC) Tj ETQq1 1 0.784314 rgBT ₉₄ /Overlook	2.1	94
169	Potency of BNT162b2 and mRNA-1273 vaccine-induced neutralizing antibodies against severe acute respiratory syndrome-CoV-2 variants of concern: A systematic review of in vitro studies. <i>Reviews in Medical Virology</i> , 2022, 32, e2277.	3.9	57
170	Regulation Mechanism for the Binding between the SARS-CoV-2 Spike Protein and Host Angiotensin-Converting Enzyme II. <i>Journal of Physical Chemistry Letters</i> , 2021, 12, 6252-6261.	2.1	12
171	Clinical Characteristics of Hospitalized COVID-19 Patients Who Received at Least One Dose of COVID-19 Vaccine. <i>Vaccines</i> , 2021, 9, 781.	2.1	28
172	SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination. <i>Cell Reports</i> , 2021, 36, 109415.	2.9	206
173	Intranasal gene therapy to prevent infection by SARS-CoV-2 variants. <i>PLoS Pathogens</i> , 2021, 17, e1009544.	2.1	36
174	The SARS-CoV-2 spike L452R-E484Q variant in the Indian B.1.617 strain showed significant reduction in the neutralization activity of immune sera. <i>Precision Clinical Medicine</i> , 2021, 4, 149-154.	1.3	7
176	poreCov-An Easy to Use, Fast, and Robust Workflow for SARS-CoV-2 Genome Reconstruction via Nanopore Sequencing. <i>Frontiers in Genetics</i> , 2021, 12, 711437.	1.1	24
177	Reduced antibody cross-reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strains. <i>ELife</i> , 2021, 10, .	2.8	42
178	The impact of spike mutated variants of SARS-CoV2 [Alpha, Beta, Gamma, Delta, and Lambda] on the efficacy of subunit recombinant vaccines. <i>Brazilian Journal of Infectious Diseases</i> , 2021, 25, 101606.	0.3	94
179	Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of Nsp14 RNA cap methyltransferase. <i>Biochemical Journal</i> , 2021, 478, 2481-2497.	1.7	39
180	Antiviral Effect of Budesonide against SARS-CoV-2. <i>Viruses</i> , 2021, 13, 1411.	1.5	13
181	Limitation of Screening of Different Variants of SARS-CoV-2 by RT-PCR. <i>Diagnostics</i> , 2021, 11, 1241.	1.3	16
182	Hypothesis: Possible influence of antivector immunity and SARS-CoV-2 variants on efficacy of ChAdOx1 nCoV-19 vaccine. <i>British Journal of Pharmacology</i> , 2022, 179, 218-226.	2.7	11
186	A Possible Role of Remdesivir and Plasma Therapy in the Selective Sweep and Emergence of New SARS-CoV-2 Variants. <i>Journal of Clinical Medicine</i> , 2021, 10, 3276.	1.0	18

#	ARTICLE	IF	CITATIONS
187	High-precision and cost-efficient sequencing for real-time COVID-19 surveillance. <i>Scientific Reports</i> , 2021, 11, 13669.	1.6	15
188	Keep out! SARS-CoV-2 entry inhibitors: their role and utility as COVID-19 therapeutics. <i>Virology Journal</i> , 2021, 18, 154.	1.4	29
191	Structural and functional basis for pan-CoV fusion inhibitors against SARS-CoV-2 and its variants with preclinical evaluation. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 288.	7.1	38
192	Living and Dying With COVID-19 in South Asian Low- and Middle-Income Countries. <i>Frontiers in Public Health</i> , 2021, 9, 600878.	1.3	3
193	Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants. <i>Nature Communications</i> , 2021, 12, 4598.	5.8	88
194	SARS-CoV-2 variant from India to Marseille: The still active role of ports in the introduction of epidemics. <i>Travel Medicine and Infectious Disease</i> , 2021, 42, 102085.	1.5	11
195	Wastewater-Based Epidemiology for Community Monitoring of SARS-CoV-2: Progress and Challenges. <i>ACS Environmental Au</i> , 2021, 1, 18-31.	3.3	33
196	A high-throughput cell- and virus-free assay shows reduced neutralization of SARS-CoV-2 variants by COVID-19 convalescent plasma. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	68
198	Evidence for antibody as a protective correlate for COVID-19 vaccines. <i>Vaccine</i> , 2021, 39, 4423-4428.	1.7	766
200	SARS-CoV-2 Neutralizing Antibodies for COVID-19 Prevention and Treatment. <i>Annual Review of Medicine</i> , 2022, 73, 1-16.	5.0	91
201	Structural dynamics of SARS-CoV-2 variants: A health monitoring strategy for anticipating Covid-19 outbreaks. <i>Journal of Infection</i> , 2021, 83, 197-206.	1.7	60
202	Fragment molecular orbital based interaction analyses on complexes between SARS-CoV-2 RBD variants and ACE2. <i>Japanese Journal of Applied Physics</i> , 2021, 60, 090901.	0.8	8
203	Molecular Level Dissection of Critical Spike Mutations in SARS-CoV-2 Variants of Concern (VOCs): A Simplified Review. <i>ChemistrySelect</i> , 2021, 6, 7981-7998.	0.7	18
204	Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 317.	7.1	68
205	Facing the wrath of enigmatic mutations: a review on the emergence of severe acute respiratory syndrome coronavirus 2 variants amid coronavirus disease-19 pandemic. <i>Environmental Microbiology</i> , 2022, 24, 2615-2629.	1.8	23
206	Results of the RENAISSANCE Study: REsponse to BNT162b2 COVID-19 vacciNeâ€”short- And long-term Immune reSponSe evALuatioN in health Care workErs. <i>Mayo Clinic Proceedings</i> , 2021, 96, 2966-2979.	1.4	18
207	Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics. <i>ELife</i> , 2021, 10, .	2.8	267
208	Inflammasome activation at the crux of severe COVID-19. <i>Nature Reviews Immunology</i> , 2021, 21, 694-703.	10.6	210

#	ARTICLE	IF	CITATIONS
209	Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. <i>Cell</i> , 2021, 184, 4220-4236.e13.	13.5	630
213	N439K Variant in Spike Protein Alter the Infection Efficiency and Antigenicity of SARS-CoV-2 Based on Molecular Dynamics Simulation. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 697035.	1.8	19
214	Jumping a Moving Train: SARS-CoV-2 Evolution in Real Time. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2021, 10, S96-S105.	0.6	9
216	Characterization of SARS-CoV-2 worldwide transmission based on evolutionary dynamics and specific viral mutations in the spike protein. <i>Infectious Diseases of Poverty</i> , 2021, 10, 112.	1.5	8
218	A SARS-CoV-2 antibody broadly neutralizes SARS-related coronaviruses and variants by coordinated recognition of a virus-vulnerable site. <i>Immunity</i> , 2021, 54, 2385-2398.e10.	6.6	46
219	Neutralization of SARS-CoV-2 by highly potent, hyperthermostable, and mutation-tolerant nanobodies. <i>EMBO Journal</i> , 2021, 40, e107985.	3.5	69
220	SARS-CoV-2 Infection: New Molecular, Phylogenetic, and Pathogenetic Insights. Efficacy of Current Vaccines and the Potential Risk of Variants. <i>Viruses</i> , 2021, 13, 1687.	1.5	57
221	The rapid adaptation of SARS-CoV-2—rise of the variants: transmission and resistance. <i>Journal of Microbiology</i> , 2021, 59, 807-818.	1.3	18
222	A modelling study investigating short and medium-term challenges for COVID-19 vaccination: From prioritisation to the relaxation of measures. <i>EClinicalMedicine</i> , 2021, 38, 101001.	3.2	45
223	Therapeutic effect of CT-P59 against SARS-CoV-2 South African variant. <i>Biochemical and Biophysical Research Communications</i> , 2021, 566, 135-140.	1.0	46
224	mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates. <i>Nature Immunology</i> , 2021, 22, 1306-1315.	7.0	57
225	Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to circulating SARS-CoV-2 variants. <i>Immunity</i> , 2021, 54, 1841-1852.e4.	6.6	114
226	Whole-Genome Sequences of SARS-CoV-2 Lineage B.1.525 Strains (Variant Î) Detected from Patients in the Abruzzo Region (Central Italy) during Spring 2021. <i>Microbiology Resource Announcements</i> , 2021, 10, e0061821.	0.3	2
228	Cross-Neutralizing Activity Against SARS-CoV-2 Variants in COVID-19 Patients: Comparison of 4 Waves of the Pandemic in Japan. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab430.	0.4	18
229	Recombinant <i>Mycobacterium paragordoniae</i> Expressing SARS-CoV-2 Receptor-Binding Domain as a Vaccine Candidate Against SARS-CoV-2 Infections. <i>Frontiers in Immunology</i> , 2021, 12, 712274.	2.2	10
232	Gastrointestinal Disease and COVID-19: A Review of Current Evidence. <i>Digestive Diseases</i> , 2022, 40, 506-514.	0.8	8
236	A highly potent antibody effective against SARS-CoV-2 variants of concern. <i>Cell Reports</i> , 2021, 37, 109814.	2.9	39
237	Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination. <i>Cell Reports Medicine</i> , 2021, 2, 100405.	3.3	110

#	ARTICLE	IF	CITATIONS
238	Revolutionizing polymer-based nanoparticle-linked vaccines for targeting respiratory viruses: A perspective. <i>Life Sciences</i> , 2021, 280, 119744.	2.0	11
239	Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern. <i>Science Translational Medicine</i> , 2021, 13, eabj5413.	5.8	79
240	SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. <i>The Cochrane Library</i> , 2021, 2021, CD013825.	1.5	114
241	Emerging SARS-CoV-2 variants follow a historical pattern recorded in outgroups infecting non-human hosts. <i>Communications Biology</i> , 2021, 4, 1134.	2.0	3
242	Application of omics technology to combat the COVID-19 pandemic. <i>MedComm</i> , 2021, 2, 381-401.	3.1	11
243	Development and preclinical evaluation of virus-like particle vaccine against COVID-19 infection. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 258-270.	2.7	27
244	An ultrapotent pan- β -coronavirus lineage B (β -CoV-B) neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved epitope. <i>Protein and Cell</i> , 2022, 13, 655-675.	4.8	25
246	Pharmacological inhibition of fatty acid synthesis blocks SARS-CoV-2 replication. <i>Nature Metabolism</i> , 2021, 3, 1466-1475.	5.1	76
248	SARS-CoV-2 Delta Variant Pathogenesis and Host Response in Syrian Hamsters. <i>Viruses</i> , 2021, 13, 1773.	1.5	43
249	Inactivation of SARS-CoV-2 isolates from lineages B.1.1.7 (Alpha), P.1 (Gamma) and B.1.110 by heating and UV irradiation. <i>Journal of Virological Methods</i> , 2021, 295, 114216.	1.0	10
250	An optimized and robust SARS-CoV-2 pseudovirus system for viral entry research. <i>Journal of Virological Methods</i> , 2021, 295, 114221.	1.0	12
251	The next phase of SARS-CoV-2 surveillance: real-time molecular epidemiology. <i>Nature Medicine</i> , 2021, 27, 1518-1524.	15.2	178
254	Broadly-Neutralizing Antibodies Against Emerging SARS-CoV-2 Variants. <i>Frontiers in Immunology</i> , 2021, 12, 752003.	2.2	62
255	Genomic sequencing of SARS-CoV-2 in Rwanda reveals the importance of incoming travelers on lineage diversity. <i>Nature Communications</i> , 2021, 12, 5705.	5.8	24
256	Vaccines for COVID-19: Where do we stand in 2021?. <i>Paediatric Respiratory Reviews</i> , 2021, 39, 22-31.	1.2	53
259	The biological and clinical significance of emerging SARS-CoV-2 variants. <i>Nature Reviews Genetics</i> , 2021, 22, 757-773.	7.7	778
261	Emerging SARS-CoV-2 Variants of Concern (VOCs): An Impending Global Crisis. <i>Biomedicines</i> , 2021, 9, 1303.	1.4	87
262	Epitope diversity of SARS-CoV-2 hyperimmune intravenous human immunoglobulins and neutralization of variants of concern. <i>IScience</i> , 2021, 24, 103006.	1.9	23

#	ARTICLE	IF	CITATIONS
263	Impact of mutations in SARS-COV-2 spike on viral infectivity and antigenicity. Briefings in Bioinformatics, 2022, 23, .	3.2	16
265	The Immune Response to SARS-CoV-2 and Variants of Concern. Viruses, 2021, 13, 1911.	1.5	18
266	Possible future waves of SARS-CoV-2 infection generated by variants of concern with a range of characteristics. Nature Communications, 2021, 12, 5730.	5.8	90
267	A Bifluorescent-Based Assay for the Identification of Neutralizing Antibodies against SARS-CoV-2 Variants of Concern <i>In Vitro</i> and <i>In Vivo</i>. Journal of Virology, 2021, 95, e0112621.	1.5	13
268	Application of Artificial Intelligence in COVID-19 Diagnosis and Therapeutics. Journal of Personalized Medicine, 2021, 11, 886.	1.1	17
270	Neutrophils and lymphopenia, an unknown axis in severe COVID-19 disease. PLoS Pathogens, 2021, 17, e1009850.	2.1	22
271	Paucity and discordance of neutralising antibody responses to SARS-CoV-2 VOCs in vaccinated immunodeficient patients and health-care workers in the UK. Lancet Microbe, The, 2021, 2, e416-e418.	3.4	16
272	Recent progress on the mutations of SARS-CoV-2 spike protein and suggestions for prevention and controlling of the pandemic. Infection, Genetics and Evolution, 2021, 93, 104971.	1.0	19
273	Humoral and cellular immunity and the safety of COVID-19 vaccines: a summary of data published by 21 May 2021. International Immunology, 2021, 33, 529-540.	1.8	28
274	Addressing the "hypoxia paradox"™ in severe COVID-19: literature review and report of four cases treated with erythropoietin analogues. Molecular Medicine, 2021, 27, 120.	1.9	9
275	Cloning of a Passage-Free SARS-CoV-2 Genome and Mutagenesis Using Red Recombination. International Journal of Molecular Sciences, 2021, 22, 10188.	1.8	30
276	Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain. Cell Reports, 2021, 37, 109822.	2.9	35
277	COVID-19 Animal Models and Vaccines: Current Landscape and Future Prospects. Vaccines, 2021, 9, 1082.	2.1	8
278	A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19. Nature Communications, 2021, 12, 5469.	5.8	102
279	Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). Lancet, The, 2021, 398, 981-990.	6.3	214
280	The real-life impact of vaccination on COVID-19 mortality in Europe and Israel. Public Health, 2021, 198, 230-237.	1.4	70
282	Development of a model-inference system for estimating epidemiological characteristics of SARS-CoV-2 variants of concern. Nature Communications, 2021, 12, 5573.	5.8	36
283	Computational prediction of the effect of amino acid changes on the binding affinity between SARS-CoV-2 spike RBD and human ACE2. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	61

#	ARTICLE	IF	CITATIONS
284	Wave-wise comparative genomic study for revealing the complete scenario and dynamic nature of COVID-19 pandemic in Bangladesh. PLoS ONE, 2021, 16, e0258019.	1.1	13
285	Specific CD8+ TCR Repertoire Recognizing Conserved Antigens of SARS-CoV-2 in Unexposed Population: A Prerequisite for Broad-Spectrum CD8+ T Cell Immunity. Vaccines, 2021, 9, 1093.	2.1	6
286	Forest-bathing and physical activity as weapons against COVID-19: a review. Environmental Chemistry Letters, 2022, 20, 131-140.	8.3	55
287	Changing composition of SARS-CoV-2 lineages and rise of Delta variant in England. EClinicalMedicine, 2021, 39, 101064.	3.2	116
289	COVID-19 Pandemic and Vaccines Update on Challenges and Resolutions. Frontiers in Cellular and Infection Microbiology, 2021, 11, 690621.	1.8	60
290	The Natural Stilbenoid (â€“) -Hopeaphenol Inhibits Cellular Entry of SARS-CoV-2 USA-WA1/2020, B.1.1.7, and B.1.351 Variants. Antimicrobial Agents and Chemotherapy, 2021, 65, e0077221.	1.4	26
291	Impact of the Delta variant on vaccine efficacy and response strategies. Expert Review of Vaccines, 2021, 20, 1201-1209.	2.0	177
292	Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors. Nature Medicine, 2021, 27, 2002-2011.	15.2	167
293	Controversy surrounding the Sputnik V vaccine. Respiratory Medicine, 2021, 187, 106569.	1.3	28
294	Trajectory of Growth of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants in Houston, Texas, January through May 2021, Based on 12,476 Genome Sequences. American Journal of Pathology, 2021, 191, 1754-1773.	1.9	26
295	Investigating the possible origin and transmission routes of SARS-CoV-2 genomes and variants of concern in Bangladesh. Infection, Genetics and Evolution, 2021, 95, 105057.	1.0	2
296	Mutations Associated with SARS-CoV-2 Variants of Concern, Benin, Early 2021. Emerging Infectious Diseases, 2021, 27, 2889-2903.	2.0	10
297	An observational study of breakthrough SARS-CoV-2 Delta variant infections among vaccinated healthcare workers in Vietnam. EClinicalMedicine, 2021, 41, 101143.	3.2	78
298	Comparative Analysis of SARS-CoV-2-Specific B Cell and Humoral Responses Elicited by Sputnik V in Naïve and COVID-19-Recovered Vaccine Recipients. SSRN Electronic Journal, 0, , .	0.4	0
299	Overview of approved and upcoming vaccines for SARS-CoV-2: a living review. Oxford Open Immunology, 2021, 2, iqab010.	1.2	18
302	Immunology of SARS-CoV-2 infections and vaccines. Advances in Immunology, 2021, 151, 49-97.	1.1	12
303	Divergence of Delta and Beta Variants and SARS-CoV-2 Evolved in Advanced HIV Disease into Two Serological Phenotypes. SSRN Electronic Journal, 0, , .	0.4	1
304	Liquid repellency enabled antipathogen coatings. Materials Today Bio, 2021, 12, 100145.	2.6	7

#	ARTICLE	IF	CITATIONS
305	Comprehensive mapping of binding hot spots of SARS-CoV-2 RBD-specific neutralizing antibodies for tracking immune escape variants. <i>Genome Medicine</i> , 2021, 13, 164.	3.6	42
306	mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. <i>Science</i> , 2021, 374, abm0829.	6.0	609
307	An Antigenic Space Framework for Understanding Antibody Escape of SARS-CoV-2 Variants. <i>Viruses</i> , 2021, 13, 2009.	1.5	9
308	Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. <i>Cell</i> , 2021, 184, 5699-5714.e11.	13.5	262
309	Resistance of SARS-CoV-2 variants to neutralization by convalescent plasma from early COVID-19 outbreak in Singapore. <i>Npj Vaccines</i> , 2021, 6, 125.	2.9	17
310	COVID-19 Risk Assessment for the Tokyo Olympic Games. <i>Frontiers in Public Health</i> , 2021, 9, 730611.	1.3	9
311	Significantly reduced abilities to cross-neutralize SARS-CoV-2 variants by sera from convalescent COVID-19 patients infected by Delta or early strains. <i>Cellular and Molecular Immunology</i> , 2021, 18, 2560-2562.	4.8	11
312	Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern. <i>Nature Microbiology</i> , 2021, 6, 1433-1442.	5.9	94
313	Subtle differences in the pathogenicity of SARS-CoV-2 variants of concern B.1.1.7 and B.1.351 in rhesus macaques. <i>Science Advances</i> , 2021, 7, eabj3627.	4.7	24
314	ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7. <i>Nature Communications</i> , 2021, 12, 5868.	5.8	52
315	Mutational Hotspot in the SARS-CoV-2 Spike Protein N-Terminal Domain Conferring Immune Escape Potential. <i>Viruses</i> , 2021, 13, 2114.	1.5	10
316	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil. <i>Nature Communications</i> , 2021, 12, 5861.	5.8	38
317	SARS-CoV-2 variants, a still unfinished story. <i>Vacunas (English Edition)</i> , 2021, 22, 167-173.	0.3	4
318	Key Substitutions in the Spike Protein of SARS-CoV-2 Variants Can Predict Resistance to Monoclonal Antibodies, but Other Substitutions Can Modify the Effects. <i>Journal of Virology</i> , 2022, 96, JVI0111021.	1.5	29
319	The global transmission of new coronavirus variants. <i>Environmental Research</i> , 2022, 206, 112240.	3.7	48
321	A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses. <i>Nature Communications</i> , 2021, 12, 6197.	5.8	61
322	Emerging SARS-CoV-2 Variants: A Review of Its Mutations, Its Implications and Vaccine Efficacy. <i>Vaccines</i> , 2021, 9, 1195.	2.1	90
323	Beta RBD boost broadens antibody-mediated protection against SARS-CoV-2 variants in animal models. <i>Cell Reports Medicine</i> , 2021, 2, 100450.	3.3	17

#	ARTICLE	IF	CITATIONS
325	Ten emerging SARS-CoV-2 spike variants exhibit variable infectivity, animal tropism, and antibody neutralization. <i>Communications Biology</i> , 2021, 4, 1196.	2.0	49
326	Sensitivity of two SARS-CoV-2 variants with spike protein mutations to neutralising antibodies. <i>Virus Genes</i> , 2021, 57, 502-509.	0.7	3
327	In Vitro Effect of Taraxacum officinale Leaf Aqueous Extract on the Interaction between ACE2 Cell Surface Receptor and SARS-CoV-2 Spike Protein D614 and Four Mutants. <i>Pharmaceuticals</i> , 2021, 14, 1055.	1.7	13
328	Neutralization of SARS-CoV-2 Variants of Concern Harboring Q677H. <i>MBio</i> , 2021, 12, e0251021.	1.8	33
329	COVID-19: A review of newly formed viral clades, pathophysiology, therapeutic strategies and current vaccination tasks. <i>International Journal of Biological Macromolecules</i> , 2021, , .	3.6	14
331	Reinfections in COVID-19 Patients: Impact of Virus Genetic Variability and Host Immunity. <i>Vaccines</i> , 2021, 9, 1168.	2.1	19
332	Rapid incidence estimation from SARS-CoV-2 genomes reveals decreased case detection in Europe during summer 2020. <i>Nature Communications</i> , 2021, 12, 6009.	5.8	17
333	Genomic reconstruction of the SARS-CoV-2 epidemic in England. <i>Nature</i> , 2021, 600, 506-511.	13.7	80
334	Evaluation of the clinical and analytical performance of the Seegene allplex [®] , [®] SARS-CoV-2 variants I assay for the detection of variants of concern (VOC) and variants of interests (VOI). <i>Journal of Clinical Virology</i> , 2021, 144, 104996.	1.6	16
335	Evidence for retained spike-binding and neutralizing activity against emerging SARS-CoV-2 variants in serum of COVID-19 mRNA vaccine recipients. <i>EBioMedicine</i> , 2021, 73, 103626.	2.7	43
336	SARS-CoV-2 monoclonal antibodies with therapeutic potential: Broad neutralizing activity and No evidence of antibody-dependent enhancement. <i>Antiviral Research</i> , 2021, 195, 105185.	1.9	5
337	Vaccine development and technology for SARS-CoV-2: Current insight. <i>Journal of Medical Virology</i> , 2022, 94, 878-896.	2.5	8
338	A natural product compound inhibits coronaviral replication in vitro by binding to the conserved Nsp9 SARS-CoV-2 protein. <i>Journal of Biological Chemistry</i> , 2021, 297, 101362.	1.6	35
339	Complete protection by a single-dose skin patch [®] delivered SARS-CoV-2 spike vaccine. <i>Science Advances</i> , 2021, 7, eabj8065.	4.7	31
340	SARS-CoV-2 beta variant substitutions alter spike glycoprotein receptor binding domain structure and stability. <i>Journal of Biological Chemistry</i> , 2021, 297, 101371.	1.6	6
341	Lives saved and hospitalizations averted by COVID-19 vaccination in New York City: a modeling study. <i>The Lancet Regional Health Americas</i> , 2022, 5, 100085.	1.5	30
342	Planning for the emergence of vaccine-resistant SARS-CoV-2: addressing revaccination delivery bottlenecks. <i>Journal of the Royal Society of Medicine</i> , 2021, 114, 014107682110526.	1.1	2
344	Effects of Severe Acute Respiratory Syndrome Coronavirus 2 Strain Variation on Virus Neutralization Titers: Therapeutic Use of Convalescent Plasma. <i>Journal of Infectious Diseases</i> , 2022, 225, 971-976.	1.9	5

#	ARTICLE	IF	CITATIONS
345	Standardised neutralising antibody assays are needed for evaluating COVID-19 vaccines. <i>EBioMedicine</i> , 2021, 73, 103677.	2.7	6
347	A review of epidemiology, clinical features and disease course, transmission dynamics, and neutralization efficacy of SARS-CoV-2 variants. <i>Egyptian Journal of Bronchology</i> , 2021, 15, .	0.3	4
348	Recombinant protein subunit SARS-CoV-2 vaccines formulated with CoVaccine HT [®] , [®] adjuvant induce broad, Th1 biased, humoral and cellular immune responses in mice. <i>Vaccine: X</i> , 2021, 9, 100126.	0.9	13
352	Potent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants. <i>Nature Communications</i> , 2021, 12, 6304.	5.8	42
353	Understanding the Secret of SARS-CoV-2 Variants of Concern/Interest and Immune Escape. <i>Frontiers in Immunology</i> , 2021, 12, 744242.	2.2	44
354	Development and characterization of SARS-CoV-2 variant-neutralizing monoclonal antibodies. <i>Antiviral Research</i> , 2021, 196, 105206.	1.9	1
355	Antibody neutralization to SARS-CoV-2 and variants after 1 year in Wuhan, China. <i>Innovation(China)</i> , 2022, 3, 100181.	5.2	8
356	ACE2 [®] : [®] S1 RBD Interaction-Targeted Peptides and Small Molecules as Potential COVID-19 Therapeutics. <i>Advances in Pharmacological and Pharmaceutical Sciences</i> , 2021, 2021, 1-10.	0.7	5
357	Update on geographical variation and distribution of SARS-nCoV-2: A systematic review. <i>Indian Journal of Pharmacology</i> , 2021, 53, 310-316.	0.4	3
358	Methodological Development of a Multi-Readout Assay for the Assessment of Antiviral Drugs against SARS-CoV-2. <i>Pathogens</i> , 2021, 10, .	1.2	3
359	Poor Antibody Response to BioNTech/Pfizer Coronavirus Disease 2019 Vaccination in Severe Acute Respiratory Syndrome Coronavirus 2 [®] Naive Residents of Nursing Homes. <i>Clinical Infectious Diseases</i> , 2022, 75, e695-e704.	2.9	23
360	Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2. <i>Theranostics</i> , 2022, 12, 1-17.	4.6	6
361	Treatment and therapeutic agents. , 2022, , 121-176.		0
362	Longitudinal analysis of SARS-CoV-2 spike and RNA-dependent RNA polymerase protein sequences reveals the emergence and geographic distribution of diverse mutations. <i>Infection, Genetics and Evolution</i> , 2022, 97, 105153.	1.0	16
363	D614G mutation and SARS-CoV-2: impact on S-protein structure, function, infectivity, and immunity. <i>Applied Microbiology and Biotechnology</i> , 2021, 105, 9035-9045.	1.7	34
364	The alpha/B.1.1.7 SARS-CoV-2 variant exhibits significantly higher affinity for ACE-2 and requires lower inoculation doses to cause disease in K18-hACE2 mice. <i>ELife</i> , 2021, 10, .	2.8	24
365	COVID [®] 19 vaccinations: The unknowns, challenges, and hopes. <i>Journal of Medical Virology</i> , 2022, 94, 1336-1349.	2.5	75
366	Alpha (B.1.1.7) and Delta (B.1.617.2 [®] AY.40) SARS-CoV-2 variants present strong neutralization decay at M4 post-vaccination and a faster replication rates than D614G (B.1) lineage. <i>Journal of Infection</i> , 2022, 84, 418-467.	1.7	4

#	ARTICLE	IF	CITATIONS
367	Functional Antibodies Against SARS-CoV-2 Receptor Binding Domain Variants with Mutations N501Y or E484K in Human Milk from COVID-19-Vaccinated, -Recovered, and -Unvaccinated Women. <i>Breastfeeding Medicine</i> , 2022, 17, 163-172.	0.8	3
368	Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. <i>Lancet Microbe</i> , The, 2022, 3, e52-e61.	3.4	436
369	Evolution of the SARS-CoV-2 genome and emergence of variants of concern. <i>Archives of Virology</i> , 2022, 167, 293-305.	0.9	28
370	N501Y and K417N Mutations in the Spike Protein of SARS-CoV-2 Alter the Interactions with Both hACE2 and Human-Derived Antibody: A Free Energy of Perturbation Retrospective Study. <i>Journal of Chemical Information and Modeling</i> , 2021, 61, 6079-6084.	2.5	74
371	Immune response against SARS-CoV-2 variants: the role of neutralization assays. <i>Npj Vaccines</i> , 2021, 6, 142.	2.9	26
373	Safety and efficacy of RNA vaccines: State of the art. <i>Medical Immunology (Russia)</i> , 2021, 23, 1017-1030.	0.1	2
374	A stem-loop RNA RIG-I agonist protects against acute and chronic SARS-CoV-2 infection in mice. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	46
377	T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naïve UK health-care workers: a multicentre prospective cohort study. <i>Lancet Microbe</i> , The, 2022, 3, e21-e31.	3.4	131
378	Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity. <i>Seminars in Immunology</i> , 2021, 55, 101533.	2.7	72
379	Immune Evasive Effects of SARS-CoV-2 Variants to COVID-19 Emergency Used Vaccines. <i>Frontiers in Immunology</i> , 2021, 12, 771242.	2.2	15
380	Phylogenomics and population genomics of SARS-CoV-2 in Mexico during the pre-vaccination stage reveals variants of interest B.1.1.28.4 and B.1.1.222 or B.1.1.519 and the nucleocapsid mutation S194L associated with symptoms. <i>Microbial Genomics</i> , 2021, 7, .	1.0	13
381	SARS-CoV-2 Variants and Their Relevant Mutational Profiles: Update Summer 2021. <i>Microbiology Spectrum</i> , 2021, 9, e0109621.	1.2	39
382	Mutation-Induced Long-Range Allosteric Interactions in the Spike Protein Determine the Infectivity of SARS-CoV-2 Emerging Variants. <i>ACS Omega</i> , 2021, 6, 31305-31320.	1.6	8
383	MG1141A as a Highly Potent Monoclonal Neutralizing Antibody Against SARS-CoV-2 Variants. <i>Frontiers in Immunology</i> , 2021, 12, 778829.	2.2	2
384	Emerging Mutations Potentially Related to SARS-CoV-2 Immune Escape: The Case of a Long-Term Patient. <i>Life</i> , 2021, 11, 1259.	1.1	2
385	Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike. <i>MBio</i> , 2021, 12, e0297521.	1.8	24
386	A Novel Strategy for the Detection of SARS-CoV-2 Variants Based on Multiplex PCR-Mass Spectrometry Minisequencing Technology. <i>Microbiology Spectrum</i> , 2021, 9, e0126721.	1.2	19
387	The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants. <i>Cell Host and Microbe</i> , 2022, 30, 53-68.e12.	5.1	52

#	ARTICLE	IF	CITATIONS
389	Population impact of SARS-CoV-2 variants with enhanced transmissibility and/or partial immune escape. <i>Cell</i> , 2021, 184, 6229-6242.e18.	13.5	72
390	SNP and Phylogenetic Characterization of Low Viral Load SARS-CoV-2 Specimens by Target Enrichment. <i>Frontiers in Virology</i> , 2021, 1, .	0.7	6
392	E484K and N501Y SARS-CoV 2 spike mutants Increase ACE2 recognition but reduce affinity for neutralizing antibody. <i>International Immunopharmacology</i> , 2022, 102, 108424.	1.7	31
394	Structure and Mutations of SARS-CoV-2 Spike Protein: A Focused Overview. <i>ACS Infectious Diseases</i> , 2022, 8, 29-58.	1.8	32
395	An immunodominant NP105â€™113-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease. <i>Nature Immunology</i> , 2022, 23, 50-61.	7.0	110
396	mRNA-Based COVID-19 Vaccine Boosters Induce Neutralizing Immunity Against SARS-CoV-2 Omicron Variant. <i>SSRN Electronic Journal</i> , 0, , .	0.4	34
397	Evolutionary Dynamics of Indels in SARS-CoV-2 Spike Glycoprotein. <i>Evolutionary Bioinformatics</i> , 2021, 17, 117693432110646.	0.6	5
398	OUP accepted manuscript. <i>Briefings in Bioinformatics</i> , 2022, , .	3.2	2
399	Fundamentals of genomic epidemiology, lessons learned from the coronavirus disease 2019 (COVID-19) pandemic, and new directions. <i>Antimicrobial Stewardship & Healthcare Epidemiology</i> , 2021, 1, .	0.2	5
400	The adaptation of SARS-CoV-2 to humans. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2022, 116, e210127.	0.8	4
401	Recent advances in nanotechnology-based COVID-19 vaccines and therapeutic antibodies. <i>Nanoscale</i> , 2022, 14, 1054-1074.	2.8	22
403	Genomic analysis of SARS-CoV-2 variants of concern identified from the ChAdOx1 nCoV-19 immunized patients from Southwest part of Bangladesh. <i>Journal of Infection and Public Health</i> , 2022, 15, 156-163.	1.9	10
404	Predictive Profiling of SARS-CoV-2 Variants by Deep Mutational Learning. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
405	Methodological Development of a Multi-Readout Assay for the Assessment of Antiviral Drugs against SARS-CoV-2. <i>Pathogens</i> , 2021, 10, 1076.	1.2	7
406	Neutralizing-antibody-independent SARS-CoV-2 control correlated with intranasal-vaccine-induced CD8+ TÂcell responses. <i>Cell Reports Medicine</i> , 2022, 3, 100520.	3.3	29
408	Mesenchymal Stem Cell-Based COVID-19 Therapy: Bioengineering Perspectives. <i>Cells</i> , 2022, 11, 465.	1.8	3
409	SARS-CoV-2 mRNA Vaccine Breakthrough Infections in Fully Vaccinated Healthcare Personnel: A Systematic Review. <i>Tropical Medicine and Infectious Disease</i> , 2022, 7, 9.	0.9	14
410	Insights on the mutational landscape of the SARS-CoV-2 Omicron variant receptor-binding domain. <i>Cell Reports Medicine</i> , 2022, 3, 100527.	3.3	47

#	ARTICLE	IF	CITATIONS
412	The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans. <i>Science Translational Medicine</i> , 2022, 14, eabl8124.	5.8	143
413	Pathogenomic analyses of <i>Shigella</i> isolates inform factors limiting shigellosis prevention and control across LMICs. <i>Nature Microbiology</i> , 2022, 7, 251-261.	5.9	23
415	An insight into SARS-CoV-2 structure, pathogenesis, target hunting for drug development and vaccine initiatives. <i>RSC Medicinal Chemistry</i> , 2022, 13, 647-675.	1.7	3
416	Preclinical immunological evaluation of an intradermal heterologous vaccine against SARS-CoV-2 variants. <i>Emerging Microbes and Infections</i> , 2022, 11, 212-226.	3.0	6
418	Comparative analyses of IgG/IgA neutralizing effects induced by three COVID-19 vaccines against variants of concern. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 1242-1252.e12.	1.5	23
419	mRNA-1273 vaccine-induced antibodies maintain Fc effector functions across SARS-CoV-2 variants of concern. <i>Immunity</i> , 2022, 55, 355-365.e4.	6.6	76
421	The ins and outs of SARS-CoV-2 variants of concern (VOCs). <i>Archives of Virology</i> , 2022, 167, 327-344.	0.9	35
422	SARS-CoV-2 Variants, Vaccines, and Host Immunity. <i>Frontiers in Immunology</i> , 2021, 12, 809244.	2.2	176
423	From Bench to the Clinic: The Path to Translation of Nanotechnology-Enabled mRNA SARS-CoV-2 Vaccines. <i>Nano-Micro Letters</i> , 2022, 14, 41.	14.4	26
424	ACE2 is the critical in vivo receptor for SARS-CoV-2 in a novel COVID-19 mouse model with TNF- and IFN γ -driven immunopathology. <i>ELife</i> , 2022, 11, .	2.8	42
425	Modeling SARS-CoV-2 spike/ACE2 protein-protein interactions for predicting the binding affinity of new spike variants for ACE2, and novel ACE2 structurally related human protein targets, for COVID-19 handling in the 3PM context. <i>EPMA Journal</i> , 2022, 13, 149-175.	3.3	28
426	An Outbreak of Breakthrough Infections by the SARS-CoV-2 Delta Variant in a Psychiatric Closed Ward. <i>Journal of Korean Medical Science</i> , 2022, 37, e28.	1.1	5
427	mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. <i>Cell</i> , 2022, 185, 457-466.e4.	13.5	881
428	Immunization with synthetic SARS-CoV-2 S glycoprotein virus-like particles protects macaques from infection. <i>Cell Reports Medicine</i> , 2022, 3, 100528.	3.3	6
429	Developing an Amplification Refractory Mutation System-Quantitative Reverse Transcription-PCR Assay for Rapid and Sensitive Screening of SARS-CoV-2 Variants of Concern. <i>Microbiology Spectrum</i> , 2022, 10, e0143821.	1.2	11
430	Mitochondrial Dysfunction Associates With Acute T Lymphocytopenia and Impaired Functionality in COVID-19 Patients. <i>Frontiers in Immunology</i> , 2021, 12, 799896.	2.2	5
431	Viral Load in COVID-19 Patients: Implications for Prognosis and Vaccine Efficacy in the Context of Emerging SARS-CoV-2 Variants. <i>Frontiers in Medicine</i> , 2021, 8, 836826.	1.2	15
432	The Variation of SARS-CoV-2 and Advanced Research on Current Vaccines. <i>Frontiers in Medicine</i> , 2021, 8, 806641.	1.2	22

#	ARTICLE	IF	CITATIONS
433	SARS-CoV-2 Variants: Differences and Potential of Immune Evasion. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 781429.	1.8	154
437	Evaluating Antibody Mediated Protection against Alpha, Beta, and Delta SARS-CoV-2 Variants of Concern in K18-hACE2 Transgenic Mice. <i>Journal of Virology</i> , 2022, 96, jvi0218421.	1.5	14
438	Limited Variation between SARS-CoV-2-Infected Individuals in Domain Specificity and Relative Potency of the Antibody Response against the Spike Glycoprotein. <i>Microbiology Spectrum</i> , 2022, 10, e0267621.	1.2	1
439	The Remarkable Evolutionary Plasticity of Coronaviruses by Mutation and Recombination: Insights for the COVID-19 Pandemic and the Future Evolutionary Paths of SARS-CoV-2. <i>Viruses</i> , 2022, 14, 78.	1.5	64
442	Receptor binding and complex structures of human ACE2 to spike RBD from omicron and delta SARS-CoV-2. <i>Cell</i> , 2022, 185, 630-640.e10.	13.5	358
443	SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. <i>Cell</i> , 2022, 185, 467-484.e15.	13.5	788
444	Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses. <i>Science Translational Medicine</i> , 2022, 14, eabn7842.	5.8	92
445	Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 Omicron. <i>Cell</i> , 2022, 185, 860-871.e13.	13.5	310
446	SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape. <i>Cell Host and Microbe</i> , 2022, 30, 154-162.e5.	5.1	153
448	Growth, Antigenicity, and Immunogenicity of SARS-CoV-2 Spike Variants Revealed by a Live rVSV-SARS-CoV-2 Virus. <i>Frontiers in Medicine</i> , 2021, 8, 793437.	1.2	4
449	Synthetic multiantigen MVA vaccine COH04S1 protects against SARS-CoV-2 in Syrian hamsters and non-human primates. <i>Npj Vaccines</i> , 2022, 7, 7.	2.9	35
450	A bivalent nanoparticle vaccine exhibits potent cross-protection against the variants of SARS-CoV-2. <i>Cell Reports</i> , 2022, 38, 110256.	2.9	19
451	Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants. <i>EBioMedicine</i> , 2022, 75, 103761.	2.7	104
452	Severe Acute Respiratory Syndrome Type 2â€Causing Coronavirus: Variants and Preventive Strategies. <i>Advanced Science</i> , 2022, 9, e2104495.	5.6	16
453	Immune dynamics of SARS-CoV-2 virus evolution. <i>International Journal of Molecular and Immuno Oncology</i> , 0, 7, 3-15.	0.0	2
454	Kinetics of immune responses to SARS-CoV-2 proteins in individuals with varying severity of infection and following a single dose of the AZD1222. <i>Clinical and Experimental Immunology</i> , 2022, 208, 323-331.	1.1	3
455	SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo. <i>Nature</i> , 2022, 603, 715-720.	13.7	577
456	Identification of cytotoxic T cells and their T cell receptor sequences targeting COVID-19 using MHC class I-binding peptides. <i>Journal of Human Genetics</i> , 2022, 67, 411-419.	1.1	5

#	ARTICLE	IF	CITATIONS
457	CoVac501, a self-adjuvanting peptide vaccine conjugated with TLR7 agonists, against SARS-CoV-2 induces protective immunity. <i>Cell Discovery</i> , 2022, 8, 9.	3.1	12
458	Increased Antibody Avidity and Cross-Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Variants by Hyperimmunized Transchromosomal Bovine-Derived Human Immunoglobulins for Treatment of Coronavirus Disease 2019. <i>Journal of Infectious Diseases</i> , 2022, 226, 655-663.	1.9	4
459	SARS-CoV-2 E484K Mutation Narrative Review: Epidemiology, Immune Escape, Clinical Implications, and Future Considerations. <i>Infection and Drug Resistance</i> , 2022, Volume 15, 373-385.	1.1	24
460	Engineered extracellular vesicles directed to the spike protein inhibit SARS-CoV-2. <i>Molecular Therapy - Methods and Clinical Development</i> , 2022, 24, 355-366.	1.8	19
461	Charge Matters: Mutations in Omicron Variant Favor Binding to Cells. <i>ChemBioChem</i> , 2022, 23, e202100681.	1.3	62
462	Mutations in the receptor-binding domain of human SARS CoV-2 spike protein increases its affinity to bind human ACE-2 receptor. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 2368-2381.	2.0	7
463	Quantifying Neutralizing Antibodies in Patients with COVID-19 by a Two-Variable Generalized Additive Model. <i>MSphere</i> , 2022, 7, e0088321.	1.3	10
464	Amantadine-assembled nanostimulator enhances dimeric RBD antigen-elicited cross-neutralization against SARS-CoV-2 strains. <i>Nano Today</i> , 2022, 43, 101393.	6.2	2
465	Multiple expansions of globally uncommon SARS-CoV-2 lineages in Nigeria. <i>Nature Communications</i> , 2022, 13, 688.	5.8	23
466	Third waves of the COVID-19 pandemic: Prominence of initial public health Interference. <i>Infectious Disorders - Drug Targets</i> , 2022, 22, .	0.4	6
467	Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection. <i>Nature Microbiology</i> , 2022, 7, 423-433.	5.9	78
468	In silico analysis of mutant epitopes in new SARS-CoV-2 lineages suggest global enhanced CD8+ T cell reactivity and also signs of immune response escape. <i>Infection, Genetics and Evolution</i> , 2022, 99, 105236.	1.0	6
470	High-affinity, neutralizing antibodies to SARS-CoV-2 can be made without T follicular helper cells. <i>Science Immunology</i> , 2022, 7, .	5.6	28
471	Escape from recognition of SARS-CoV-2 variant spike epitopes but overall preservation of T cell immunity. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	77
472	Socio-demographic Heterogeneity in Prevalence of SARS-COV-2 Infection and Death Rate: Relevance to Black College Student Knowledge of COVID-19 and SARS-COV-2. <i>Journal of Racial and Ethnic Health Disparities</i> , 2022, , 1.	1.8	2
473	Co-circulation of SARS-CoV-2 Alpha and Gamma variants in Italy, February and March 2021. <i>Eurosurveillance</i> , 2022, 27, .	3.9	20
474	A Detailed Overview of Immune Escape, Antibody Escape, Partial Vaccine Escape of SARS-CoV-2 and Their Emerging Variants With Escape Mutations. <i>Frontiers in Immunology</i> , 2022, 13, 801522.	2.2	73
475	Divergent SARS-CoV-2 Omicron-reactive T and B cell responses in COVID-19 vaccine recipients. <i>Science Immunology</i> , 2022, 7, eabo2202.	5.6	337

#	ARTICLE	IF	CITATIONS
476	Structural and biochemical rationale for enhanced spike protein fitness in delta and kappa SARS-CoV-2 variants. <i>Nature Communications</i> , 2022, 13, 742.	5.8	71
477	A SARS-CoV-2 variant elicits an antibody response with a shifted immunodominance hierarchy. <i>PLoS Pathogens</i> , 2022, 18, e1010248.	2.1	48
478	Parallel profiling of antigenicity alteration and immune escape of SARS-CoV-2 Omicron and other variants. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 42.	7.1	25
480	Emerging SARS-CoV-2 Variants: Genetic Variability and Clinical Implications. <i>Current Microbiology</i> , 2022, 79, 20.	1.0	48
481	In-Silico Design of a Novel Tridecapeptide Targeting Spike Protein of SARS-CoV-2 Variants of Concern. <i>International Journal of Peptide Research and Therapeutics</i> , 2022, 28, 28.	0.9	12
482	Antibody affinity maturation and cross-variant activity following SARS-CoV-2 mRNA vaccination: Impact of prior exposure and sex. <i>EBioMedicine</i> , 2021, 74, 103748.	2.7	17
483	Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. <i>Nature</i> , 0, , .	13.7	104
484	The germinal centre B cell response to SARS-CoV-2. <i>Nature Reviews Immunology</i> , 2022, 22, 7-18.	10.6	150
485	Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. <i>Nature</i> , 2022, 602, 654-656.	13.7	928
486	A serum-stable RNA aptamer specific for SARS-CoV-2 neutralizes viral entry. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	58
487	Elucidating the role of N440K mutation in SARS-CoV-2 spike " ACE-2 binding affinity and COVID-19 severity by virtual screening, molecular docking and dynamics approach. <i>Journal of Biomolecular Structure and Dynamics</i> , 2021, , 1-18.	2.0	11
499	Emergence of SARS-CoV-2 resistance mutations in a patient who received anti-SARS-COV2 spike protein monoclonal antibodies: a case report. <i>BMC Infectious Diseases</i> , 2021, 21, 1223.	1.3	7
500	Biparatopic nanobodies protect mice from lethal challenge with SARS-CoV-2 variants of concern. <i>EMBO Reports</i> , 2022, 23, e53865.	2.0	18
501	SARS-CoV-2 Delta Variant Displays Moderate Resistance to Neutralizing Antibodies and Spike Protein Properties of Higher Soluble ACE2 Sensitivity, Enhanced Cleavage and Fusogenic Activity. <i>Viruses</i> , 2021, 13, 2485.	1.5	23
502	Hyperglycosylated spike of SARS-CoV-2 gamma variant induces breast cancer metastasis. <i>American Journal of Cancer Research</i> , 2021, 11, 4994-5005.	1.4	0
503	Infection of wild-type mice by SARS-CoV-2 B.1.351 variant indicates a possible novel cross-species transmission route. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 420.	7.1	46
504	Both simulation and sequencing data reveal coinfections with multiple SARS-CoV-2 variants in the COVID-19 pandemic. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 1389-1401.	1.9	7
505	Inhibitor screening using microarray identifies the high capacity of neutralizing antibodies to Spike variants in SARS-CoV-2 infection and vaccination. <i>Theranostics</i> , 2022, 12, 2519-2534.	4.6	3

#	ARTICLE	IF	CITATIONS
507	SARS-CoV-2 and Coronavirus Disease Mitigation: Treatment Options, Vaccinations and Variants. <i>Pathogens</i> , 2022, 11, 275.	1.2	9
508	Design of a mutation-integrated trimeric RBD with broad protection against SARS-CoV-2. <i>Cell Discovery</i> , 2022, 8, 17.	3.1	23
509	COVID-19 vaccine development based on recombinant viral and bacterial vector systems: combinatorial effect of adaptive and trained immunity. <i>Journal of Microbiology</i> , 2022, 60, 321-334.	1.3	12
511	COVID-19 Vaccine: Between Myth and Truth. <i>Vaccines</i> , 2022, 10, 349.	2.1	12
513	SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies. <i>Science</i> , 2022, 375, 782-787.	6.0	60
514	Classical and Next-Generation Vaccine Platforms to SARS-CoV-2: Biotechnological Strategies and Genomic Variants. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 2392.	1.2	11
515	Memory B Cells Induced by Sputnik V Vaccination Produce SARS-CoV-2 Neutralizing Antibodies Upon Ex Vivo Restimulation. <i>Frontiers in Immunology</i> , 2022, 13, 840707.	2.2	11
516	Broad ultra-potent neutralization of SARS-CoV-2 variants by monoclonal antibodies specific to the tip of RBD. <i>Cell Discovery</i> , 2022, 8, 16.	3.1	18
517	Cooperative multivalent receptor binding promotes exposure of the SARS-CoV-2 fusion machinery core. <i>Nature Communications</i> , 2022, 13, 1002.	5.8	30
518	Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial (PROTECT-Patient Trial). <i>Scientific Reports</i> , 2022, 12, 2552.	1.6	23
519	Emergence and spread of a sub-lineage of SARS-CoV-2 Alpha variant B.1.1.7 in Europe, and with further evolution of spike mutation accumulations shared with the Beta and Gamma variants. <i>Virus Evolution</i> , 2022, 8, veac010.	2.2	10
520	BNT162b2 vaccination enhances interferon-JAK-STAT-regulated antiviral programs in COVID-19 patients infected with the SARS-CoV-2 Beta variant. <i>Communications Medicine</i> , 2022, 2, .	1.9	18
522	SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern. <i>ELife</i> , 2022, 11, .	2.8	26
523	An engineered bispecific human monoclonal antibody against SARS-CoV-2. <i>Nature Immunology</i> , 2022, 23, 423-430.	7.0	38
526	Evolutionary dynamics of the severe acute respiratory syndrome coronavirus 2 genomes. <i>Medical Review</i> , 2022, 2, 3-22.	0.3	7
528	Structure/Function Analysis of Truncated Amino-Terminal ACE2 Peptide Analogs That Bind to SARS-CoV-2 Spike Glycoprotein. <i>Molecules</i> , 2022, 27, 2070.	1.7	3
529	Monoclonal antibody targeting the conserved region of the SARS-CoV-2 spike protein to overcome viral variants. <i>JCI Insight</i> , 2022, 7, .	2.3	10
530	Rationally designed immunogens enable immune focusing following SARS-CoV-2 spike imprinting. <i>Cell Reports</i> , 2022, 38, 110561.	2.9	16

#	ARTICLE	IF	CITATIONS
532	SARS-CoV-2 mRNA vaccine induced higher antibody affinity and IgG titers against variants of concern in post-partum vs non-post-partum women. <i>EBioMedicine</i> , 2022, 77, 103940.	2.7	3
533	Computation of Antigenicity Predicts SARS-CoV-2 Vaccine Breakthrough Variants. <i>Frontiers in Immunology</i> , 2022, 13, 861050.	2.2	8
534	Poxvirus MVA Expressing SARS-CoV-2 S Protein Induces Robust Immunity and Protects Rhesus Macaques From SARS-CoV-2. <i>Frontiers in Immunology</i> , 2022, 13, 845887.	2.2	13
535	Immunogenicity of ChAdOx1 nCoV-19 vaccine after a two-dose inactivated SARS-CoV-2 vaccination of dialysis patients and kidney transplant recipients. <i>Scientific Reports</i> , 2022, 12, 3587.	1.6	17
536	Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion. <i>MBio</i> , 2022, 13, e0009922.	1.8	22
537	High avidity of vaccine-induced immunoglobulin G against SARS-CoV-2: potential relevance for protective humoral immunity. <i>Exploration of Immunology</i> , 0, , 133-156.	1.7	7
538	Competition for refueling rather than cyclic reentry initiation evident in germinal centers. <i>Science Immunology</i> , 2022, 7, eabm0775.	5.6	23
539	Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617. <i>Nature Communications</i> , 2022, 13, 1638.	5.8	11
540	Impact of new variants on SARS-CoV-2 infectivity and neutralization: A molecular assessment of the alterations in the spike-host protein interactions. <i>IScience</i> , 2022, 25, 103939.	1.9	32
541	Antigen-antibody complex-guided exploration of the hotspots conferring the immune-escaping ability of the SARS-CoV-2 RBD. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 797132.	1.6	3
542	Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection. <i>Science Translational Medicine</i> , 2022, 14, eabn8057.	5.8	150
543	Neutralizing antibodies to SARS-CoV-2 Omicron variant after third mRNA vaccination in health care workers and elderly subjects. <i>European Journal of Immunology</i> , 2022, 52, 816-824.	1.6	31
544	The Immune Response, Safety, and Efficacy of Emergency Use Authorization-Granted COVID-19 Vaccines: A Review. <i>Open Microbiology Journal</i> , 2022, 16, .	0.2	1
547	Divergent trajectories of antiviral memory after SARS-CoV-2 infection. <i>Nature Communications</i> , 2022, 13, 1251.	5.8	20
548	The immunology and immunopathology of COVID-19. <i>Science</i> , 2022, 375, 1122-1127.	6.0	434
549	Functional analysis of polymorphisms at the S1/S2 site of SARS-CoV-2 spike protein. <i>PLoS ONE</i> , 2022, 17, e0265453.	1.1	8
550	A modified vaccinia Ankara vaccine expressing spike and nucleocapsid protects rhesus macaques against SARS-CoV-2 Delta infection. <i>Science Immunology</i> , 2022, 7, eabo0226.	5.6	22
551	Breakthrough SARS-CoV-2 infections after vaccination: a critical review. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-5.	1.4	6

#	ARTICLE	IF	CITATIONS
552	A Palmitic Acid-Conjugated, Peptide-Based pan-CoV Fusion Inhibitor Potently Inhibits Infection of SARS-CoV-2 Omicron and Other Variants of Concern. <i>Viruses</i> , 2022, 14, 549.	1.5	13
553	Transmissibility and pathogenicity of SARS-CoV-2 variants in animal models. <i>Journal of Microbiology</i> , 2022, 60, 255-267.	1.3	9
554	Immunogenicity and protective efficacy of a recombinant protein subunit vaccine and an inactivated vaccine against SARS-CoV-2 variants in non-human primates. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 69.	7.1	19
555	Specific Detection of SARS-CoV-2 Variants B.1.1.7 (Alpha) and B.1.617.2 (Delta) Using a One-Step Quantitative PCR Assay. <i>Microbiology Spectrum</i> , 2022, 10, e0217621.	1.2	9
556	Cross-species tropism and antigenic landscapes of circulating SARS-CoV-2 variants. <i>Cell Reports</i> , 2022, 38, 110558.	2.9	15
557	High-Integrity Sequencing of Spike Gene for SARS-CoV-2 Variant Determination. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3257.	1.8	4
558	Neutralizing Monoclonal Antibodies Inhibit SARS-CoV-2 Infection through Blocking Membrane Fusion. <i>Microbiology Spectrum</i> , 2022, 10, e0181421.	1.2	9
559	The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies. <i>EBioMedicine</i> , 2022, 77, 103902.	2.7	23
560	Immunotherapy and CRISPR Cas Systems: Potential Cure of COVID-19?. <i>Drug Design, Development and Therapy</i> , 2022, Volume 16, 951-972.	2.0	4
561	Nucleic Acid-Based COVID-19 Therapy Targeting Cytokine Storms: Strategies to Quell the Storm. <i>Journal of Personalized Medicine</i> , 2022, 12, 386.	1.1	5
562	SARS-CoV-2 variants and vulnerability at the global level. <i>Journal of Medical Virology</i> , 2022, 94, 2986-3005.	2.5	79
564	Spike protein of SARS-CoV-2 variants: a brief review and practical implications. <i>Brazilian Journal of Microbiology</i> , 2022, 53, 1133-1157.	0.8	22
565	Immune evasion and chronological decrease in titer of neutralizing antibody against SARS-CoV-2 and its variants of concerns in COVID-19 patients. <i>Clinical Immunology</i> , 2022, 238, 108999.	1.4	10
566	RBD trimer mRNA vaccine elicits broad and protective immune responses against SARS-CoV-2 variants. <i>IScience</i> , 2022, 25, 104043.	1.9	19
567	Molecular Dynamics and MM-PBSA Analysis of the SARS-CoV-2 Gamma Variant in Complex with the hACE-2 Receptor. <i>Molecules</i> , 2022, 27, 2370.	1.7	10
568	Kappa-RBD produced by glycoengineered <i>Pichia pastoris</i> elicited high neutralizing antibody titers against pseudoviruses of SARS-CoV-2 variants. <i>Virology</i> , 2022, 569, 56-63.	1.1	6
569	The spike-ACE2 binding assay: An in vitro platform for evaluating vaccination efficacy and for screening SARS-CoV-2 inhibitors and neutralizing antibodies. <i>Journal of Immunological Methods</i> , 2022, 503, 113244.	0.6	11
570	Neutralization or enhancement of SARS-CoV-2 infection by a monoclonal antibody targeting a specific epitope in the spike receptor-binding domain. <i>Antiviral Research</i> , 2022, 200, 105290.	1.9	3

#	ARTICLE	IF	CITATIONS
572	The status and analysis of common mutations found in the SARS-CoV-2 whole genome sequences from Bangladesh. <i>Gene Reports</i> , 2022, 27, 101608.	0.4	2
575	Molecular Evolution of Severe Acute Respiratory Syndrome Coronavirus 2: Hazardous and More Hazardous Strains Behind the Coronavirus Disease 2019 Pandemic and Their Targeting by Drugs and Vaccines. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 763687.	1.8	3
580	A Stabilized, Monomeric, Receptor Binding Domain Elicits High-Titer Neutralizing Antibodies Against All SARS-CoV-2 Variants of Concern. <i>Frontiers in Immunology</i> , 2021, 12, 765211.	2.2	16
581	SARS-CoV-2 Variants: Mutations and Effective Changes. <i>Biotechnology and Bioprocess Engineering</i> , 2021, 26, 859-870.	1.4	12
582	A Highly Conserved Peptide Vaccine Candidate Activates Both Humoral and Cellular Immunity Against SARS-CoV-2 Variant Strains. <i>Frontiers in Immunology</i> , 2021, 12, 789905.	2.2	7
583	Mutational landscape of SARS-CoV-2 genome in Turkey and impact of mutations on spike protein structure. <i>PLoS ONE</i> , 2021, 16, e0260438.	1.1	6
584	The Development of SARS-CoV-2 Variants: The Gene Makes the Disease. <i>Journal of Developmental Biology</i> , 2021, 9, 58.	0.9	27
585	Tracking SARS-CoV-2 Spike Protein Mutations in the United States (January 2020â€”March 2021) Using a Statistical Learning Strategy. <i>Viruses</i> , 2022, 14, 9.	1.5	10
586	Earlier In Vitro Viral Production With SARS-CoV-2 Alpha Than With Beta, Gamma, B, or A.27 Variants. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 792202.	1.8	1
588	Allosteric Modulation of Small Molecule Drugs on ACE2 Conformational Change upon Binding to SARS-CoV-2 Spike Protein. , 2021, , .		5
589	A Promising Vaccination Strategy against COVID-19 on the Horizon: Heterologous Immunization. <i>Journal of Microbiology and Biotechnology</i> , 2021, 31, 1601-1614.	0.9	8
591	SARS-CoV-2 Infection Causes Hyperglycemia in Cats. <i>Journal of Infectious Diseases</i> , 2022, 226, 1568-1576.	1.9	4
592	Asymptomatic Transmissibility Calls for Implementing a Zero-COVID Strategy to End the Current Global Crisis. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, 836409.	1.8	5
593	A Capsid Virus-Like Particle-Based SARS-CoV-2 Vaccine Induces High Levels of Antibodies and Protects Rhesus Macaques. <i>Frontiers in Immunology</i> , 2022, 13, 857440.	2.2	15
594	ChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variants. <i>Cell Reports</i> , 2022, 39, 110757.	2.9	10
596	Computer Simulations and Network-Based Profiling of Binding and Allosteric Interactions of SARS-CoV-2 Spike Variant Complexes and the Host Receptor: Dissecting the Mechanistic Effects of the Delta and Omicron Mutations. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4376.	1.8	16
597	Investigations on SARS-CoV-2 Susceptibility of Domestic and Wild Animals Using Primary Cell Culture Models Derived from the Upper and Lower Respiratory Tract. <i>Viruses</i> , 2022, 14, 828.	1.5	10
598	Research progress on vaccine efficacy against SARS-CoV-2 variants of concern. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-12.	1.4	10

#	ARTICLE	IF	CITATIONS
599	Single Immunization with Recombinant ACAM2000 Vaccinia Viruses Expressing the Spike and the Nucleocapsid Proteins Protects Hamsters against SARS-CoV-2-Caused Clinical Disease. <i>Journal of Virology</i> , 2022, 96, e0038922.	1.5	5
600	Impact of SARS-CoV-2 Gamma lineage introduction and COVID-19 vaccination on the epidemiological landscape of a Brazilian city. <i>Communications Medicine</i> , 2022, 2, .	1.9	32
601	Development of antibody resistance in emerging mutant strains of SARS CoV-2: Impediment for COVID-19 vaccines. <i>Reviews in Medical Virology</i> , 2022, 32, e2346.	3.9	16
602	Susceptibility to SARS-CoV-2 Virus Variants of Concern in Mouse Models. <i>Problemy Osobo Opasnykh Infektsii</i> , 2022, , 148-155.	0.2	4
603	Comparable Post-Vaccination Decay of Neutralizing Antibody Response to Wild-Type and Delta SARS-CoV-2 Variant in Healthcare Workers Recovered from Mild or Asymptomatic Infection. <i>Vaccines</i> , 2022, 10, 580.	2.1	2
604	Functional Analysis of Spike from SARS-CoV-2 Variants Reveals the Role of Distinct Mutations in Neutralization Potential and Viral Infectivity. <i>Viruses</i> , 2022, 14, 803.	1.5	10
605	Preclinical study of a DNA vaccine targeting SARS-CoV-2. <i>Current Research in Translational Medicine</i> , 2022, 70, 103348.	1.2	9
607	Phylogenetic and phylodynamic approaches to understanding and combating the early SARS-CoV-2 pandemic. <i>Nature Reviews Genetics</i> , 2022, 23, 547-562.	7.7	70
608	Identification of SARS-CoV-2 variants using viral sequencing for the Centers for Disease Control and Prevention genomic surveillance program. <i>BMC Infectious Diseases</i> , 2022, 22, 404.	1.3	24
610	High-affinity, neutralizing antibodies to SARS-CoV-2 can be made without T follicular helper cells.. <i>Science Immunology</i> , 2021, , eabl5652.	5.6	6
611	Escape from recognition of SARS-CoV-2 Beta variant spike epitopes but overall preservation of T cell immunity.. <i>Science Translational Medicine</i> , 2021, , eabj6824.	5.8	11
612	Tixagevimab/Cilgavimab for Treatment of Hospitalised COVID-19 Patients: A Randomised, Double-Blind, Phase 3 Trial. <i>SSRN Electronic Journal</i> , 0, , .	0.4	3
613	Rapid Genotyping of Sars-Cov-2 Variants with a Duplex-Targeting Lateral Flow Strip by Crispr-Cas 12a/13a in Pam Independent Manner. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
614	The E484K Substitution in a SARS-CoV-2 Spike Protein Subunit Vaccine Resulted in Limited Cross-Reactive Neutralizing Antibody Responses in Mice. <i>Viruses</i> , 2022, 14, 854.	1.5	5
615	Variant-specific vaccination induces systems immune responses and potent in vivo protection against SARS-CoV-2. <i>Cell Reports Medicine</i> , 2022, 3, 100634.	3.3	10
617	Broadly neutralizing antibodies against Omicron-included SARS-CoV-2 variants induced by vaccination. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 139.	7.1	14
618	Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2. <i>Cell Host and Microbe</i> , 2022, 30, 1093-1102.e3.	5.1	114
619	A Bivalent COVID-19 Vaccine Based on Alpha and Beta Variants Elicits Potent and Broad Immune Responses in Mice against SARS-CoV-2 Variants. <i>Vaccines</i> , 2022, 10, 702.	2.1	18

#	ARTICLE	IF	CITATIONS
620	Photonics enabled intelligence system to identify SARS-CoV 2 mutations. Applied Microbiology and Biotechnology, 2022, 106, 3321-3336.	1.7	11
621	Characterization and functional interrogation of the SARS-CoV-2 RNA interactome. Cell Reports, 2022, 39, 110744.	2.9	30
622	Disentangling the relative importance of T cell responses in COVID-19: leading actors or supporting cast?. Nature Reviews Immunology, 2022, 22, 387-397.	10.6	93
623	Safety and immunogenicity of the Pfizer/BioNTech SARS-CoV-2 mRNA third booster vaccine dose against the BA.1 and BA.2 Omicron variants. Med, 2022, 3, 406-421.e4.	2.2	17
624	An overview of current drugs and prophylactic vaccines for coronavirus disease 2019 (COVID-19). Cellular and Molecular Biology Letters, 2022, 27, 38.	2.7	11
625	Delta variant (B.1.617.2) of SARS-CoV-2: Mutations, impact, challenges and possible solutions. Human Vaccines and Immunotherapeutics, 2022, 18, 2068883.	1.4	44
626	Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine. JAMA Network Open, 2022, 5, e2210780.	2.8	27
627	Pseudotyped Bat Coronavirus RaTG13 is efficiently neutralised by convalescent sera from SARS-CoV-2 infected patients. Communications Biology, 2022, 5, 409.	2.0	5
628	Durable immunogenicity, adaptation to emerging variants, and low-dose efficacy of an AAV-based COVID-19 vaccine platform in macaques. Molecular Therapy, 2022, 30, 2952-2967.	3.7	2
629	COVID-19 vaccine development: milestones, lessons and prospects. Signal Transduction and Targeted Therapy, 2022, 7, 146.	7.1	153
630	Hexamerization of Anti-SARS CoV IgG1 Antibodies Improves Neutralization Capacity. Frontiers in Immunology, 2022, 13, .	2.2	2
631	COVID-19 in patients with hematologic malignancy. Blood, 2022, 140, 236-252.	0.6	69
632	Antibody-mediated neutralization of SARS-CoV-2. Immunity, 2022, 55, 925-944.	6.6	74
633	Quadrivalent mosaic HexaPro-bearing nanoparticle vaccine protects against infection of SARS-CoV-2 variants. Nature Communications, 2022, 13, 2674.	5.8	26
634	Statistical Challenges in Tracking the Evolution of SARS-CoV-2. Statistical Science, 2022, 37, .	1.6	7
635	Characterization of the SARS-CoV-2 B.1.621 (Mu) variant. Science Translational Medicine, 2022, 14, eabm4908.	5.8	21
636	Long-Lived Immunity in SARS-CoV-2-Recovered Children and Its Neutralizing Capacity Against Omicron. Frontiers in Immunology, 2022, 13, .	2.2	15
637	Ultrapotent and broad neutralization of SARS-CoV-2 variants by modular, tetravalent, bi-paratopic antibodies. Cell Reports, 2022, 39, 110905.	2.9	5

#	ARTICLE	IF	CITATIONS
638	Molecular evolution and structural analyses of the spike glycoprotein from Brazilian SARS-CoV-2 genomes: the impact of selected mutations. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 3110-3128.	2.0	1
639	SARS-CoV-2 humoral immune response in patients with cardiovascular risk factors: the COmmunity Cohort Study protocol. <i>BMJ Open</i> , 2022, 12, e061345.	0.8	2
640	Neutralization assays for SARS-CoV-2: Implications for assessment of protective efficacy of COVID-19 vaccines. <i>Indian Journal of Medical Research</i> , 2022, 155, 105.	0.4	2
641	Prioritizing COVID-19 vaccination. Part 2: Real-time comparison between single-dose and double-dose in Japan. <i>Mathematical Biosciences and Engineering</i> , 2022, 19, 7410-7424.	1.0	5
642	Prioritizing COVID-19 vaccination. Part 1: Final size comparison between a single dose and double dose. <i>Mathematical Biosciences and Engineering</i> , 2022, 19, 7374-7387.	1.0	3
643	High prevalence of an alpha variant lineage with a premature stop codon in ORF7a in Iraq, winter 2020â€“2021. <i>PLoS ONE</i> , 2022, 17, e0267295.	1.1	8
644	Cross-reactive immunity against the SARS-CoV-2 Omicron variant is low in pediatric patients with prior COVID-19 or MIS-C. <i>Nature Communications</i> , 2022, 13, .	5.8	36
647	Potent cross-reactive antibodies following Omicron breakthrough in vaccinees. <i>Cell</i> , 2022, 185, 2116-2131.e18.	13.5	105
648	Detecting Potentially Adaptive Mutations from the Parallel and Fixed Patterns in SARS-CoV-2 Evolution. <i>Viruses</i> , 2022, 14, 1087.	1.5	4
649	The Biological Functions and Clinical Significance of SARS-CoV-2 Variants of Concern. <i>Frontiers in Medicine</i> , 2022, 9, .	1.2	43
651	Lebanese SARS-CoV-2 genomics: 24 months of the pandemic. <i>Virus Research</i> , 2022, 317, 198824.	1.1	2
652	COH04S1 and beta sequence-modified vaccine protect hamsters from SARS-CoV-2 variants. <i>IScience</i> , 2022, 25, 104457.	1.9	8
654	Characteristics of COVID-19 Breakthrough Infections among Vaccinated Individuals and Associated Risk Factors: A Systematic Review. <i>Tropical Medicine and Infectious Disease</i> , 2022, 7, 81.	0.9	15
655	Platform for isolation and characterization of SARS-CoV-2 variants enables rapid characterization of Omicron in Australia. <i>Nature Microbiology</i> , 2022, 7, 896-908.	5.9	32
656	Real-Word Effectiveness of Global COVID-19 Vaccines Against SARS-CoV-2 Variants: A Systematic Review and Meta-Analysis. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	25
657	Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis. <i>BMC Medicine</i> , 2022, 20, .	2.3	149
658	Covid-19, an unfinished story. <i>Presse Medicale</i> , 2022, 51, 104131.	0.8	8
659	Preclinical Assessment of IgY Antibodies Against Recombinant SARS-CoV-2 RBD Protein for Prophylaxis and Post-Infection Treatment of COVID-19. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	13

#	ARTICLE	IF	CITATIONS
660	Biological Properties of SARS-CoV-2 Variants: Epidemiological Impact and Clinical Consequences. <i>Vaccines</i> , 2022, 10, 919.	2.1	23
662	Proper Selection of In Vitro Cell Model Affects the Characterization of the Neutralizing Antibody Response against SARS-CoV-2. <i>Viruses</i> , 2022, 14, 1232.	1.5	2
663	Rapid evaluation of COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 variants by analysis of genetic distance. <i>Nature Medicine</i> , 2022, 28, 1715-1722.	15.2	29
664	Atlas of currently available human neutralizing antibodies against SARS-CoV-2 and escape by Omicron sub-variants BA.1/BA.1.1/BA.2/BA.3. <i>Immunity</i> , 2022, 55, 1501-1514.e3.	6.6	59
665	Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. <i>Cell</i> , 2022, 185, 2422-2433.e13.	13.5	532
666	The Cross-Protective Immunity Landscape Among Different SARS-CoV-2 Variant RBDs. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
667	Inactivated whole-virion vaccine BBV152/Covaxin elicits robust cellular immune memory to SARS-CoV-2 and variants of concern. <i>Nature Microbiology</i> , 2022, 7, 974-985.	5.9	30
668	Induction of Broadly Cross-Reactive Antibody Responses to SARS-CoV-2 Variants by S1 Nanoparticle Vaccines. <i>Journal of Virology</i> , 0, , .	1.5	3
669	Potent human broadly SARS-CoV-2 neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	34
670	Intranasal vaccination of hamsters with a Newcastle disease virus vector expressing the S1 subunit protects animals against SARS-CoV-2 disease. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
672	SARS-CoV-2: phenotype, genotype, and characterization of different variants. <i>Cellular and Molecular Biology Letters</i> , 2022, 27, .	2.7	12
674	Rapid and accurate identification of SARS-CoV-2 Omicron variants using droplet digital PCR (RT-ddPCR). <i>Journal of Clinical Virology</i> , 2022, 154, 105218.	1.6	12
675	Structural Plasticity and Immune Evasion of SARS-CoV-2 Spike Variants. <i>Viruses</i> , 2022, 14, 1255.	1.5	30
676	Immunogenicity and Reactogenicity of Ad26.COVS.2 in Korean Adults: A Prospective Cohort Study. <i>Journal of Korean Medical Science</i> , 2022, 37, .	1.1	1
677	Frustration-driven allosteric regulation and signal transmission in the SARS-CoV-2 spike omicron trimer structures: a crosstalk of the omicron mutation sites allosterically regulates tradeoffs of protein stability and conformational adaptability. <i>Physical Chemistry Chemical Physics</i> , 0, , .	1.3	9
678	The spike glycoprotein of highly pathogenic human coronaviruses: structural insights for understanding infection, evolution and inhibition. <i>FEBS Open Bio</i> , 2022, 12, 1602-1622.	1.0	6
679	Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	59
680	Tissue immunity to SARS-CoV-2: Role in protection and immunopathology*. <i>Immunological Reviews</i> , 2022, 309, 25-39.	2.8	11

#	ARTICLE	IF	CITATIONS
681	Tixagevimab and cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2022, 10, 972-984.	5.2	61
682	Broader-species receptor binding and structural bases of Omicron SARS-CoV-2 to both mouse and palm-civet ACE2s. <i>Cell Discovery</i> , 2022, 8, .	3.1	23
683	Peptidomimetic inhibitors of TMPRSS2 block SARS-CoV-2 infection in cell culture. <i>Communications Biology</i> , 2022, 5, .	2.0	6
684	Modelling the response to vaccine in non-human primates to define SARS-CoV-2 mechanistic correlates of protection. <i>ELife</i> , 0, 11, .	2.8	7
685	Clinical grade ACE2 as a universal agent to block SARS-CoV-2 variants. <i>EMBO Molecular Medicine</i> , 2022, 14, .	3.3	35
687	Suppression of SARS-CoV-2 Replication with Stabilized and Click Chemistry Modified siRNAs. <i>Angewandte Chemie - International Edition</i> , 2022, 61, .	7.2	6
688	Whole-genome analysis and mutation pattern of SARS-CoV-2 during first and second wave outbreak in Gwangju, Republic of Korea. <i>Scientific Reports</i> , 2022, 12, .	1.6	6
689	Plasma and memory antibody responses to Gamma SARS-CoV-2 provide limited cross-protection to other variants. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	6
690	Antibodies to the Spike Protein Receptor-Binding Domain of SARS-CoV-2 at 4-13 Months after COVID-19. <i>Journal of Clinical Medicine</i> , 2022, 11, 4053.	1.0	2
691	Novel Lateral Flow-Based Assay for Simple and Visual Detection of SARS-CoV-2 Mutations. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	1
692	Suppression of SARS-CoV-2 Replication with Stabilized and Click Chemistry Modified siRNAs. <i>Angewandte Chemie</i> , 0, , .	1.6	0
694	Immunogenicity and safety of SpikoGen [®] , an adjuvanted recombinant SARS-CoV-2 spike protein vaccine as a homologous and heterologous booster vaccination: A randomized placebo-controlled trial. <i>Immunology</i> , 2022, 167, 340-353.	2.0	26
696	Potent neutralizing anti-SARS-CoV-2 human antibodies cure infection with SARS-CoV-2 variants in hamster model. <i>IScience</i> , 2022, 25, 104705.	1.9	8
698	Vaccination with Omicron Inactivated Vaccine in Pre-vaccinated Mice Protects against SARS-CoV-2 Prototype and Omicron Variants. <i>Vaccines</i> , 2022, 10, 1149.	2.1	7
699	The trispesific DARPIn ensovibep inhibits diverse SARS-CoV-2 variants. <i>Nature Biotechnology</i> , 2022, 40, 1845-1854.	9.4	25
700	SARS-CoV-2 and Emerging Foodborne Pathogens: Intriguing Commonalities and Obvious Differences. <i>Pathogens</i> , 2022, 11, 837.	1.2	0
701	Potent and Broad Neutralization of SARS-CoV-2 Variants of Concern (VOCs) including Omicron Sub-lineages BA.1 and BA.2 by Biparatopic Human VH Domains. <i>IScience</i> , 2022, , 104798.	1.9	1
702	Antibody responses and SARS-CoV-2 infection after BNT162b2 mRNA booster vaccination among healthcare workers in Japan. <i>Journal of Infection and Chemotherapy</i> , 2022, 28, 1483-1488.	0.8	3

#	ARTICLE	IF	CITATIONS
703	Comparative characterization of antibody responses induced by Ad5-vectored spike proteins of emerging SARS-CoV-2 VOCs. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	5
705	SARS-CoV-2 VOC type and biological sex affect molnupiravir efficacy in severe COVID-19 dwarf hamster model. <i>Nature Communications</i> , 2022, 13, .	5.8	24
706	SARS-CoV-2 S2-targeted vaccination elicits broadly neutralizing antibodies. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	57
707	Eleven-month longitudinal study of antibodies in SARS-CoV-2 exposed and naïve primary health care workers upon COVID-19 vaccination. <i>Immunology</i> , 2022, 167, 528-543.	2.0	2
708	Understanding the Excitation Wavelength Dependence and Thermal Stability of the SARS-CoV-2 Receptor-Binding Domain Using Surface-Enhanced Raman Scattering and Machine Learning. <i>ACS Photonics</i> , 2022, 9, 2963-2972.	3.2	10
709	A Rapid and Sensitive Microfluidics-Based Tool for Seroprevalence Immunity Assessment of COVID-19 and Vaccination-Induced Humoral Antibody Response at the Point of Care. <i>Biosensors</i> , 2022, 12, 621.	2.3	7
710	Evolutionary progression of collective mutations in Omicron sub-lineages towards efficient RBD-hACE2: Allosteric communications between and within viral and human proteins. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 4562-4578.	1.9	3
711	Heterologous immunity induced by 1st generation COVID-19 vaccines and its role in developing a pan-coronavirus vaccine. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
712	Antibody escape and cryptic cross-domain stabilization in the SARS-CoV-2 Omicron spike protein. <i>Cell Host and Microbe</i> , 2022, 30, 1242-1254.e6.	5.1	27
713	PEDOT:PSS in Solution Form Exhibits Strong Potential in Inhibiting SARS-CoV-2 Infection of the Host Cells by Targeting Viruses and Also the Host Cells. <i>Biomacromolecules</i> , 2022, 23, 3535-3548.	2.6	4
714	A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern. <i>Journal of Virology</i> , 2022, 96, .	1.5	14
715	Impaired immunity and high attack rates caused by SARS-CoV-2 variants among vaccinated long-term care facility residents. <i>Immunity, Inflammation and Disease</i> , 2022, 10, .	1.3	3
716	Humoral responses to the SARS-CoV-2 spike and receptor binding domain in context of pre-existing immunity confer broad sarbecovirus neutralization. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
717	Molecular Dynamics Analysis of Fast-Spreading Severe Acute Respiratory Syndrome Coronavirus 2 Variants and Their Effects on the Interaction with Human Angiotensin-Converting Enzyme 2. <i>ACS Omega</i> , 2022, 7, 30700-30709.	1.6	6
718	Latest in COVID-19 Vaccine 'Candidates' Race. <i>Infectious Disorders - Drug Targets</i> , 2022, 22, .	0.4	0
719	Two Years into the COVID-19 Pandemic: Lessons Learned. <i>ACS Infectious Diseases</i> , 2022, 8, 1758-1814.	1.8	47
722	Design and Immunoinformatic Assessment of Candidate Multivariant mRNA Vaccine Construct against Immune Escape Variants of SARS-CoV-2. <i>Polymers</i> , 2022, 14, 3263.	2.0	3
723	Single-Nanoparticle-Based Digital SERS Sensing Platform for the Accurate Quantitative Detection of SARS-CoV-2. <i>ACS Applied Materials & Interfaces</i> , 2022, 14, 38459-38470.	4.0	13

#	ARTICLE	IF	CITATIONS
724	Qualification of a Biolayer Interferometry Assay to Support AZD7442 Resistance Monitoring. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	2
725	A broader neutralizing antibody against all the current VOCs and VOIs targets unique epitope of SARS-CoV-2 RBD. <i>Cell Discovery</i> , 2022, 8, .	3.1	1
726	Quantitative, multiplexed, targeted proteomics for ascertaining variant specific SARS-CoV-2 antibody response. <i>Cell Reports Methods</i> , 2022, 2, 100279.	1.4	3
727	Monitoring of Both Humoral and Cellular Immunities Could Early Predict COVID-19 Vaccine Efficacy Against the Different SARS-CoV2 Variants. <i>Journal of Clinical Immunology</i> , 2023, 43, 31-45.	2.0	4
728	Safety and immunogenicity of anti-SARS-CoV-2 heterologous scheme with SOBERANA 02 and SOBERANA Plus vaccines: Phase IIb clinical trial in adults. <i>Med</i> , 2022, 3, 760-773.e5.	2.2	13
729	ChAdOx1 nCoV-19 (AZD1222) or nCoV-19-Beta (AZD2816) protect Syrian hamsters against Beta Delta and Omicron variants. <i>Nature Communications</i> , 2022, 13, .	5.8	23
730	Optimised Non-Coding Regions of mRNA SARS-CoV-2 Vaccine CV2CoV Improves Homologous and Heterologous Neutralising Antibody Responses. <i>Vaccines</i> , 2022, 10, 1251.	2.1	10
731	Neutralizing antibodies to SARS-CoV-2 variants of concern including Delta and Omicron in subjects receiving mRNA-1273, BNT162b2, and Ad26.COV2.S vaccines. <i>Journal of Medical Virology</i> , 2022, 94, 5678-5690.	2.5	16
732	Structural insights into the binding of SARS-CoV-2, SARS-CoV, and hCoV-NL63 spike receptor-binding domain to horse ACE2. <i>Structure</i> , 2022, 30, 1432-1442.e4.	1.6	18
733	Potential medicinal plants involved in inhibiting 3CLpro activity: A practical alternate approach to combating COVID-19. <i>Journal of Integrative Medicine</i> , 2022, 20, 488-496.	1.4	4
734	Neutralizing antibody responses in vaccinated and unvaccinated individuals infected with Omicron BA.1 variant. <i>Journal of Clinical Virology</i> , 2022, 155, 105253.	1.6	6
735	The mechanisms of immune response and evasion by the main SARS-CoV-2 variants. <i>IScience</i> , 2022, 25, 105044.	1.9	8
736	Antibody-mediated immunity to SARS-CoV-2 spike. <i>Advances in Immunology</i> , 2022, , 1-69.	1.1	12
737	Computational investigation of peptidomimetics as potential inhibitors of SARS-CoV-2 spike protein. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 7144-7157.	2.0	2
738	Assessing the Impact of SARS-CoV-2 Lineages and Mutations on Patient Survival. <i>Viruses</i> , 2022, 14, 1893.	1.5	3
739	Deep mutational learning predicts ACE2 binding and antibody escape to combinatorial mutations in the SARS-CoV-2 receptor-binding domain. <i>Cell</i> , 2022, 185, 4008-4022.e14.	13.5	55
740	Design of immunogens for eliciting antibody responses that may protect against SARS-CoV-2 variants. <i>PLoS Computational Biology</i> , 2022, 18, e1010563.	1.5	4
741	New insights into human immune memory from SARS-CoV-2 infection and vaccination. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 0, , .	2.7	5

#	ARTICLE	IF	CITATIONS
742	T-Cell Responses Induced by an Intradermal BNT162b2 mRNA Vaccine Booster Following Primary Vaccination with Inactivated SARS-CoV-2 Vaccine. <i>Vaccines</i> , 2022, 10, 1494.	2.1	6
743	Potential of conserved antigenic sites in development of universal SARS-like coronavirus vaccines. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
744	The neutralization of B.1.617.1 and B.1.1.529 sera from convalescent patients and BBIBP-CorV vaccines. <i>IScience</i> , 2022, 25, 105016.	1.9	2
745	Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 Omicron and Delta variants in preclinical models. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	55
747	Pre-existing anti-HCoV-OC43 immunity influences the durability and cross-reactivity of humoral response to SARS-CoV-2 vaccination. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	8
748	SARS-CoV-2 variants from COVID-19 positive cases in the Free State province, South Africa from July 2020 to December 2021. <i>Frontiers in Virology</i> , 0, 2, .	0.7	2
749	Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral response. <i>Oncolimmunology</i> , 2022, 11, .	2.1	10
752	A recombinant subunit vaccine candidate produced in plants elicits neutralizing antibodies against SARS-CoV-2 variants in macaques. <i>Frontiers in Plant Science</i> , 0, 13, .	1.7	3
754	An opinion on Wastewater-Based Epidemiological Monitoring (WBEM) with Clinical Diagnostic Test (CDT) for detecting high-prevalence areas of community COVID-19 infections. <i>Current Opinion in Environmental Science and Health</i> , 2023, 31, 100396.	2.1	20
755	Importancia de la vigilancia genómica de SARS-CoV-2 en los tiempos de las vacunas contra la COVID-19. <i>Revista De La Universidad Industrial De Santander Salud</i> , 2022, 54, .	0.0	0
756	Perspective Chapter: Real-Time Genomic Surveillance for SARS-CoV-2 on Center Stage. <i>Infectious Diseases</i> , 0, , .	4.0	0
757	Clinical Added Value of SARS-CoV-2 Antigen Detection in Blood Samples. <i>Diagnostics</i> , 2022, 12, 2427.	1.3	3
758	The Relationship between Mustard Import and COVID-19 Deaths: A Workflow with Cross-Country Text Mining. <i>Healthcare (Switzerland)</i> , 2022, 10, 2071.	1.0	0
759	Broad Antiviral Effects of <i>Echinacea purpurea</i> against SARS-CoV-2 Variants of Concern and Potential Mechanism of Action. <i>Microorganisms</i> , 2022, 10, 2145.	1.6	3
760	COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection. <i>Journal of Biomedical Science</i> , 2022, 29, .	2.6	77
761	Evaluation of the systemic and mucosal immune response induced by COVID-19 and the BNT162b2 mRNA vaccine for SARS-CoV-2. <i>PLoS ONE</i> , 2022, 17, e0263861.	1.1	12
762	The Comparison of Mutational Progression in SARS-CoV-2: A Short Updated Overview. <i>Journal of Molecular Pathology</i> , 2022, 3, 201-218.	0.5	13
763	Effect on the conformations of the spike protein of SARS-CoV-2 due to mutation. <i>Biotechnology and Applied Biochemistry</i> , 2023, 70, 979-991.	1.4	2

#	ARTICLE	IF	CITATIONS
764	SARS-CoV-2 down-regulates ACE2 through lysosomal degradation. <i>Molecular Biology of the Cell</i> , 2022, 33, .	0.9	19
765	Arylcoumarin perturbs SARS-CoV-2 pathogenesis by targeting the S-protein/ACE2 interaction. <i>Scientific Reports</i> , 2022, 12, .	1.6	0
767	Tixagevimab/cilgavimab for prevention and treatment of COVID-19: a review. <i>Expert Review of Anti-Infective Therapy</i> , 0, , 1-11.	2.0	3
769	Comparative analysis of within-host diversity among vaccinated COVID-19 patients infected with different SARS-CoV-2 variants. <i>IScience</i> , 2022, 25, 105438.	1.9	6
770	Early suppression of antiviral host response and protocadherins by SARS-CoV-2 Spike protein in THP-1-derived macrophage-like cells. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
771	Extended SARS-CoV-2 RBD booster vaccination induces humoral and cellular immune tolerance in mice. <i>IScience</i> , 2022, 25, 105479.	1.9	24
773	High-Throughput Molecular Dynamics-Based Alchemical Free Energy Calculations for Predicting the Binding Free Energy Change Associated with the Selected Omicron Mutations in the Spike Receptor-Binding Domain of SARS-CoV-2. <i>Biomedicines</i> , 2022, 10, 2779.	1.4	2
774	Bioinformatic Analysis of B- and T-cell Epitopes from SARS-CoV-2 Structural Proteins and their Potential Cross-reactivity with Emerging Variants and other Human Coronaviruses. <i>Archives of Medical Research</i> , 2022, 53, 694-710.	1.5	5
775	SARS-CoV-2 variants of concern surveillance including Omicron using RT-PCR-based genotyping offers comparable performance to whole genome sequencing. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	1
776	Fractal fractional age-structure study of omicron SARS-CoV-2 variant transmission dynamics. <i>Partial Differential Equations in Applied Mathematics</i> , 2022, 6, 100455.	1.3	7
777	SARS-CoV-2 Omicron (BA.1 and BA.2) specific novel CD8+ and CD4+ T cell epitopes targeting spike protein. <i>Immunoinformatics</i> , 2022, 8, 100020.	1.2	2
778	Novel coronavirus mutations: Vaccine development and challenges. <i>Microbial Pathogenesis</i> , 2022, 173, 105828.	1.3	7
779	Mutations in SARS-CoV-2: Insights on structure, variants, vaccines, and biomedical interventions. <i>Biomedicine and Pharmacotherapy</i> , 2023, 157, 113977.	2.5	66
780	The impact of vaccination on patients with COVID-19 during the wave of Omicron in Shanghai. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	3
781	Potent SARS-CoV-2 neutralizing antibodies with therapeutic effects in two animal models. <i>IScience</i> , 2022, 25, 105596.	1.9	8
782	Merging microfluidics with luminescence immunoassays for urgent point-of-care diagnostics of COVID-19. <i>TrAC - Trends in Analytical Chemistry</i> , 2022, 157, 116814.	5.8	13
783	A receptor-binding domain-based nanoparticle vaccine elicits durable neutralizing antibody responses against SARS-CoV-2 and variants of concern. <i>Emerging Microbes and Infections</i> , 2023, 12, .	3.0	5
784	Molecular dynamics study on the strengthening behavior of Delta and Omicron SARS-CoV-2 spike RBD improved receptor-binding affinity. <i>PLoS ONE</i> , 2022, 17, e0277745.	1.1	4

#	ARTICLE	IF	CITATIONS
785	Maturation of SARS-CoV-2 Spike-specific memory B cells drives resilience to viral escape. <i>IScience</i> , 2023, 26, 105726.	1.9	9
787	COVID-19 in Patients with Hematologic Diseases. <i>Biomedicines</i> , 2022, 10, 3069.	1.4	3
788	Structural evolution of Delta lineage of SARS-CoV-2. <i>International Journal of Biological Macromolecules</i> , 2023, 226, 1116-1140.	3.6	5
789	Investigating SARS-CoV-2 breakthrough infections per variant and vaccine type. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	5
790	Humoral immunity and B-cell memory in response to SARS-CoV-2 infection and vaccination. <i>Biochemical Society Transactions</i> , 2022, 50, 1643-1658.	1.6	6
791	Challenges and developments in universal vaccine design against SARS-CoV-2 variants. <i>Npj Vaccines</i> , 2022, 7, .	2.9	25
792	Developing Biosensors for SARS-CoV-2 Wastewater-Based Epidemiology: A Systematic Review of Trends, Limitations and Future Perspectives. <i>Sustainability</i> , 2022, 14, 16761.	1.6	2
793	Optimized ACE2 decoys neutralize antibody-resistant SARS-CoV-2 variants through functional receptor mimicry and treat infection in vivo. <i>Science Advances</i> , 2022, 8, .	4.7	9
796	A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75. <i>Cell Reports</i> , 2023, 42, 111903.	2.9	34
797	Macrophages and γ T cells interplay during SARS-CoV-2 variants infection. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
798	Key mutations in the spike protein of SARS-CoV-2 affecting neutralization resistance and viral internalization. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	15
799	Current and Emerging Knowledge in COVID-19. <i>Radiology</i> , 2023, 306, .	3.6	30
800	A bivalent subunit vaccine efficiently produced in <i>Pichia pastoris</i> against SARS-CoV-2 and emerging variants. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	2
802	Genome Structure, Life Cycle, and Taxonomy of Coronaviruses and the Evolution of SARS-CoV-2. <i>Current Topics in Microbiology and Immunology</i> , 2023, , 305-339.	0.7	3
803	Expanding repertoire of SARS-CoV-2 deletion mutations contributes to evolution of highly transmissible variants. <i>Scientific Reports</i> , 2023, 13, .	1.6	3
804	Cross-immunity against SARS-COV-2 variants of concern in naturally infected critically ill COVID-19 patients. <i>Heliyon</i> , 2023, 9, e12704.	1.4	2
805	S Trimer Derived from SARS-CoV-2 B.1.351 and B.1.618 Induced Effective Immune Response against Multiple SARS-CoV-2 Variants. <i>Vaccines</i> , 2023, 11, 193.	2.1	1
806	A perspective on SARS-CoV-2 virus-like particles vaccines. <i>International Immunopharmacology</i> , 2023, 115, 109650.	1.7	6

#	ARTICLE	IF	CITATIONS
807	A highly efficient needle-free-injection delivery system for mRNA-LNP vaccination against SARS-CoV-2. <i>Nano Today</i> , 2023, 48, 101730.	6.2	10
808	Major royal jelly proteins elicited suppression of SARS-CoV-2 entry and replication with halting lung injury. <i>International Journal of Biological Macromolecules</i> , 2023, 228, 715-731.	3.6	4
809	The frequency of defective genomes in Omicron differs from that of the Alpha, Beta and Delta variants. <i>Scientific Reports</i> , 2022, 12, .	1.6	1
811	Detection of Circulating SARS-CoV-2 Variants of Concern (VOCs) Using a Multiallelic Spectral Genotyping Assay. <i>Life</i> , 2023, 13, 304.	1.1	3
812	Alpha to Omicron (Variants of Concern): Mutation Journey, Vaccines, and Therapy. <i>Viral Immunology</i> , 0, , .	0.6	1
813	Clinical efficacy and long-term immunogenicity of an early triple dose regimen of SARS-CoV-2 mRNA vaccination in cancer patients. <i>Annals of the Academy of Medicine, Singapore</i> , 2023, 52, 8-16.	0.2	1
815	SARS-CoV-2 infection and immune responses. <i>AIMS Microbiology</i> , 2023, 9, 245-276.	1.0	2
816	SARS-CoV-2 nucleocapsid: Biological functions and implication for disease diagnosis and vaccine design. <i>Reviews in Medical Virology</i> , 2023, 33, .	3.9	7
817	An overview of the vaccine platforms to combat COVID-19 with a focus on the subunit vaccines. <i>Progress in Biophysics and Molecular Biology</i> , 2023, 178, 32-49.	1.4	16
818	Application of germline antibody features to vaccine development, antibody discovery, antibody optimization and disease diagnosis. <i>Biotechnology Advances</i> , 2023, 65, 108143.	6.0	4
819	Safety and efficacy of COVID-19 prime-boost vaccinations: Homologous BBIBP-CorV versus heterologous BNT162b2 boosters in BBIBP-CorV-primed individuals. <i>Vaccine</i> , 2023, 41, 1925-1933.	1.7	11
820	mRNA Vaccine Mitigates SARS-CoV-2 Infections and COVID-19. <i>Microbiology Spectrum</i> , 2023, 11, .	1.2	5
822	The landscape of antibody binding affinity in SARS-CoV-2 Omicron BA.1 evolution. <i>ELife</i> , 0, 12, .	2.8	21
824	Therapeutic equine hyperimmune antibodies with high and broad-spectrum neutralizing activity protect rodents against SARS-CoV-2 infection. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
825	Virus-like Particles of Nodavirus Displaying the Receptor Binding Domain of SARS-CoV-2 Spike Protein: A Potential VLP-Based COVID-19 Vaccine. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4398.	1.8	0
826	Immunogenicity and protection of a variant nanoparticle vaccine that confers broad neutralization against SARS-CoV-2 variants. <i>Nature Communications</i> , 2023, 14, .	5.8	8
827	Site of vulnerability on SARS-CoV-2 spike induces broadly protective antibody against antigenically distinct Omicron subvariants. <i>Journal of Clinical Investigation</i> , 2023, 133, .	3.9	4
828	Mechanisms that promote the evolution of cross-reactive antibodies upon vaccination with designed influenza immunogens. <i>Cell Reports</i> , 2023, 42, 112160.	2.9	1

#	ARTICLE	IF	CITATIONS
829	CRISPR techniques and potential for the detection and discrimination of SARS-CoV-2 variants of concern. <i>TrAC - Trends in Analytical Chemistry</i> , 2023, 161, 117000.	5.8	11
830	Rapid escape of new SARS-CoV-2 Omicron variants from BA.2-directed antibody responses. <i>Cell Reports</i> , 2023, 42, 112271.	2.9	12
832	An update on SARS-CoV-2 immunization and future directions. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	2
833	SARS-CoV-2 epitope-specific T cells: Immunity response feature, TCR repertoire characteristics and cross-reactivity. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
834	Amount of antigen, T follicular helper cells and affinity of founder cells shape the diversity of germinal center B cells: A computational study. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	4
835	Synthetic multiantigen MVA vaccine COH04S1 and variant-specific derivatives protect Syrian hamsters from SARS-CoV-2 Omicron subvariants. <i>Npj Vaccines</i> , 2023, 8, .	2.9	7
836	Longer intervals between SARS-CoV-2 infection and mRNA-1273 doses improve the neutralization of different variants of concern. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	1
837	A high-resolution melt curve toolkit to identify lineage-defining SARS-CoV-2 mutations. <i>Scientific Reports</i> , 2023, 13, .	1.6	0
838	A combination of vaccination, early multiple-round overall screening, traditional Chinese medicine intervention and "treatment window forward" can reduce the proportion of severe and critical patients with SARS-CoV-2 B.1.617.2 (Delta) variant infection" Experience from the COVID-19 treatment center of Heilongjiang Province. <i>Journal of Translational Critical Care Medicine</i> , 2023, 5, .	0.0	0
839	The origins of new SARS-COV-2 variants in immunocompromised individuals. <i>Current Opinion in HIV and AIDS</i> , 2023, 18, 148-156.	1.5	3
840	Understanding Mutations in Human SARS-CoV-2 Spike Glycoprotein: A Systematic Review & Meta-Analysis. <i>Viruses</i> , 2023, 15, 856.	1.5	10
841	Evolution of Immune Evasion and Host Range Expansion by the SARS-CoV-2 B.1.1.529 (Omicron) Variant. <i>MBio</i> , 2023, 14, .	1.8	9
842	Genotype "phenotype landscapes for immune "pathogen coevolution. <i>Trends in Immunology</i> , 2023, 44, 384-396.	2.9	3
843	The evolution of SARS-CoV-2. <i>Nature Reviews Microbiology</i> , 2023, 21, 361-379.	13.6	239
844	<i>Immunology of COVID-19</i> . , 2024, , 52-71.		0
845	<i>SARS-CoV-2: Structure, Pathogenesis, and Diagnosis</i> . , 2024, , 24-51.		0
846	SARS-CoV-2 evolved variants optimize binding to cellular glycocalyx. <i>Cell Reports Physical Science</i> , 2023, 4, 101346.	2.8	12
847	Potent Omicron-neutralizing antibodies isolated from a patient vaccinated 6 months before Omicron emergence. <i>Cell Reports</i> , 2023, 42, 112421.	2.9	3

#	ARTICLE	IF	CITATIONS
848	The importance of combining serological testing with RT-PCR assays for efficient detection of COVID-19 and higher diagnostic accuracy. PeerJ, 0, 11, e15024.	0.9	4
849	Analysis of SARS-CoV-2 variants from patient specimens in Nevada from October 2020 to August 2021. Infection, Genetics and Evolution, 2023, 111, 105434.	1.0	1
850	Inactivated vaccine-elicited potent antibodies can broadly neutralize SARS-CoV-2 circulating variants. Nature Communications, 2023, 14, .	5.8	12
851	Temporal dynamics and fatality of SARS-CoV-2 variants in Bangladesh. Health Science Reports, 2023, 6, .	0.6	0
852	Next-Generation Vaccines against COVID-19 Variants: Beyond the Spike Protein. Zoonoses, 2023, 3, .	0.5	1
853	COVID-19 vaccines based on viral nanoparticles displaying a conserved B-cell epitope show potent immunogenicity and a long-lasting antibody response. Frontiers in Microbiology, 0, 14, .	1.5	2
883	Adopting Autodock Koto for Virtual Screening of COVID-19. Lecture Notes in Computer Science, 2023, , 752-763.	1.0	0
889	Chronicling the 3-year evolution of the COVID-19 pandemic: analysis of disease management, characteristics of major variants, and impacts on pathogenicity. Clinical and Experimental Medicine, 0, , .	1.9	0
899	Role of cellular fatty acids in combating the corona virus. , 2023, , 439-453.		0
924	Structure-Based Screening of Potential Drugs against SARS-CoV-2 Variants. , 0, , .		0